Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16867168,t1/2,The mean t1/2 of solifenacin was extended from 49.3 to 77.5 hr whereas time to Cmax did not change.,Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867168/),h,49.3 to 77.5,435,DB01026,Ketoconazole
,27943222,protein binding,Cediranib binds to serum albumin and α1-acid glycoprotein; protein binding in human plasma is approximately 95%.,Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27943222/),%,95,597,DB01026,Ketoconazole
,27943222,terminal half-life,The apparent oral clearance is moderate and the mean terminal half-life is 22 h.,Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27943222/),h,22,598,DB01026,Ketoconazole
,11557914,heart rate,"As expected, heart rate increased from baseline (approximately 8-11 beats/min) at > or =8 mg reboxetine daily.",Lack of effect of reboxetine on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557914/),[beats] / [min],8-11,2265,DB01026,Ketoconazole
,11180024,unbound plasma level,"Ketoconazole significantly elevated ritonavir CSF concentration by 178% (95% CI, 59%-385%), from 2.4 to 6.6 ng/mL, with no change in paired unbound plasma level (26 ng/mL); this led to a commensurate 181% increase (95% CI, 47%-437%) in CSF/plasma unbound ratio.",Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180024/),[ng] / [ml],26,2307,DB01026,Ketoconazole
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,35,3347,DB01026,Ketoconazole
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,50,3348,DB01026,Ketoconazole
,16640453,protein binding,Ranolazine protein binding is about 61-64% over the therapeutic concentration range.,Clinical pharmacokinetics of ranolazine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,61-64,3349,DB01026,Ketoconazole
,16640453,Volume of distribution at steady state,Volume of distribution at steady state ranges from 85 to 180 L.,Clinical pharmacokinetics of ranolazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),l,85 to 180,3350,DB01026,Ketoconazole
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,1.4-1.9,3351,DB01026,Ketoconazole
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,7,3352,DB01026,Ketoconazole
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],45,3353,DB01026,Ketoconazole
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],33,3354,DB01026,Ketoconazole
,2747741,unbound fractions,The unbound fractions of ketoconazole in SBF (2.3%) and CBF (1.2%) were calculated from plasma protein binding (99.0%).,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),%,2.3,6290,DB01026,Ketoconazole
,2747741,unbound fractions,The unbound fractions of ketoconazole in SBF (2.3%) and CBF (1.2%) were calculated from plasma protein binding (99.0%).,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),%,1.2,6291,DB01026,Ketoconazole
,2747741,unbound fractions,The unbound fractions of ketoconazole in SBF (2.3%) and CBF (1.2%) were calculated from plasma protein binding (99.0%).,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),%,99.0,6292,DB01026,Ketoconazole
,2747741,unbound,"Before the ultimate dose, levels of unbound ketoconazole in SBF and CBF were 0.64 +/- 0.16 and 0.70 +/- 0.25 ng/ml and were thus in accordance with free ketoconazole serum levels (0.52 +/- 0.24 ng/ml; p greater than 0.05).",Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],0.64,6293,DB01026,Ketoconazole
,2747741,unbound,"Before the ultimate dose, levels of unbound ketoconazole in SBF and CBF were 0.64 +/- 0.16 and 0.70 +/- 0.25 ng/ml and were thus in accordance with free ketoconazole serum levels (0.52 +/- 0.24 ng/ml; p greater than 0.05).",Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],0.70,6294,DB01026,Ketoconazole
,2747741,unbound,"Before the ultimate dose, levels of unbound ketoconazole in SBF and CBF were 0.64 +/- 0.16 and 0.70 +/- 0.25 ng/ml and were thus in accordance with free ketoconazole serum levels (0.52 +/- 0.24 ng/ml; p greater than 0.05).",Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),ng,0.52,6295,DB01026,Ketoconazole
,2747741,Peak concentrations,Peak concentrations of free ketoconazole were (SBF) 8.6 +/- 2.9 ng/ml and (CBF) 8.9 +/- 2.3 ng/ml.,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],8.6,6296,DB01026,Ketoconazole
,2747741,Peak concentrations,Peak concentrations of free ketoconazole were (SBF) 8.6 +/- 2.9 ng/ml and (CBF) 8.9 +/- 2.3 ng/ml.,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],8.9,6297,DB01026,Ketoconazole
,2747741,CBF,Peak concentrations of free ketoconazole were (SBF) 8.6 +/- 2.9 ng/ml and (CBF) 8.9 +/- 2.3 ng/ml.,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],8.9,6298,DB01026,Ketoconazole
,17544609,retention times,"The retention times of VRC and IS were approximately 3.3 and 2.7 min, respectively.",Validation of rapid and simple LC-MS/MS method for determination of voriconazole in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17544609/),min,3.3,6331,DB01026,Ketoconazole
,17544609,retention times,"The retention times of VRC and IS were approximately 3.3 and 2.7 min, respectively.",Validation of rapid and simple LC-MS/MS method for determination of voriconazole in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17544609/),min,2.7,6332,DB01026,Ketoconazole
,20233203,metabolic AUC ratio (AUC(last),"The metabolic AUC ratio (AUC(last) of DA-8164/AUC(last) of udenafil) was 1.71 when udenafil was administered alone, and the value decreased to 0.19 when udenafil was dosed in the presence of ketoconazole.",Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233203/),,1.71,8116,DB01026,Ketoconazole
,20233203,metabolic AUC ratio (AUC(last),"The metabolic AUC ratio (AUC(last) of DA-8164/AUC(last) of udenafil) was 1.71 when udenafil was administered alone, and the value decreased to 0.19 when udenafil was dosed in the presence of ketoconazole.",Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233203/),,0.19,8117,DB01026,Ketoconazole
,15664364,m,"BLA and I.S. were determined by multiple reaction monitoring using precursor-->product ion combinations at m/z 644.6-->584.3 and 531.2-->81.6, respectively.",Determination of bulleyaconitine A in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664364/),,644.6,9076,DB01026,Ketoconazole
,15664364,m,"BLA and I.S. were determined by multiple reaction monitoring using precursor-->product ion combinations at m/z 644.6-->584.3 and 531.2-->81.6, respectively.",Determination of bulleyaconitine A in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664364/),,584.3,9077,DB01026,Ketoconazole
,15664364,m,"BLA and I.S. were determined by multiple reaction monitoring using precursor-->product ion combinations at m/z 644.6-->584.3 and 531.2-->81.6, respectively.",Determination of bulleyaconitine A in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664364/),,531.2,9078,DB01026,Ketoconazole
,15664364,recoveries,The recoveries of BLA ranged from 96.93 to 113.9% and the R.S.D. was within 20%.,Determination of bulleyaconitine A in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664364/),%,96.93 to 113.9,9079,DB01026,Ketoconazole
,17310470,limit of detection,The limit of detection for each analyte was 1 ng/mL.,Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),[ng] / [ml],1,10156,DB01026,Ketoconazole
,17310470,overall recoveries,"The overall recoveries for docetaxel and ketoconazole were about 89.0% and 91.1%, respectively.",Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),%,89.0,10157,DB01026,Ketoconazole
,17310470,overall recoveries,"The overall recoveries for docetaxel and ketoconazole were about 89.0% and 91.1%, respectively.",Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),%,91.1,10158,DB01026,Ketoconazole
,17310470,total analysis time,The total analysis time was only 9.0 min.,Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),min,9.0,10159,DB01026,Ketoconazole
,29749631,half-life,Posttreatment washout of posaconazole was slow in normals (mean half-life 36 hours) and further prolonged in obese subjects (64 hours).,Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29749631/),h,36,10238,DB01026,Ketoconazole
,29749631,half-life,Posttreatment washout of posaconazole was slow in normals (mean half-life 36 hours) and further prolonged in obese subjects (64 hours).,Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29749631/),h,64,10239,DB01026,Ketoconazole
,8513654,time to maximum concentration,The mean metabolite area under the concentration-time curve increased by 34% and the time to maximum concentration of the metabolite was delayed from 2.3 to 4 hours by concurrent fluconazole.,The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513654/),h,2.3,11297,DB01026,Ketoconazole
,8513654,time to maximum concentration,The mean metabolite area under the concentration-time curve increased by 34% and the time to maximum concentration of the metabolite was delayed from 2.3 to 4 hours by concurrent fluconazole.,The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513654/),h,4,11298,DB01026,Ketoconazole
,3576671,ED50,"The dose that produced 50% of the maximal immunosuppression (ED50) for cyclosporine alone was 89 mg/kg/day, whereas the ED50 for cyclosporine, when combined with ketoconazole, was 33 mg/kg/day.",Pharmacodynamics of cyclosporine-ketoconazole interaction in mice. Combined therapy potentiates cyclosporine immunosuppression and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576671/),[mg] / [d·kg],33,11465,DB01026,Ketoconazole
,24079718,bile-to-plasma AUC ratio,"High concentrations of the active form was measured in bile with a bile-to-plasma AUC ratio of approximately 75, indicating involvement of transporter-mediated excretion of the compound.",Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24079718/),,75,11794,DB01026,Ketoconazole
,12047483,tmax,"Bosentan was absorbed and eliminated with a tmax of 4.5 h (range 3.5-6.0 h) and a t(1/2) of 5.4 h (95% CI; 4.5, 6.6).",Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047483/),h,4.5,12545,DB01026,Ketoconazole
,12047483,t(1/2),"Bosentan was absorbed and eliminated with a tmax of 4.5 h (range 3.5-6.0 h) and a t(1/2) of 5.4 h (95% CI; 4.5, 6.6).",Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047483/),h,5.4,12546,DB01026,Ketoconazole
,7618346,clearance,2. The clearance of both UK 101613 (15.4 +/- 1.9 ml/min) and UK 102333 (14.9 +/- 1.6 ml/min) was limited by hepatic bloodflow.,Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618346/),[ml] / [min],15.4,12609,DB01026,Ketoconazole
,7618346,clearance,2. The clearance of both UK 101613 (15.4 +/- 1.9 ml/min) and UK 102333 (14.9 +/- 1.6 ml/min) was limited by hepatic bloodflow.,Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618346/),[ml] / [min],14.9,12610,DB01026,Ketoconazole
,7618346,apparent biliary clearance,"The apparent biliary clearance of UK 101613 (10.3 +/- 2.3 ml/min) was less than perfusate clearance, indicating accumulation within the hepatocytes.",Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618346/),[ml] / [min],10.3,12611,DB01026,Ketoconazole
>,7618346,hepatic extraction,"4. Although the compounds are of similar structure and have a similar hepatic extraction (> 0.9), UK 101613 had an apparent biliary clearance approximately twice that of UK 102333.",Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618346/),,0.9,12612,DB01026,Ketoconazole
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],6.6,12867,DB01026,Ketoconazole
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],26,12868,DB01026,Ketoconazole
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,22,12869,DB01026,Ketoconazole
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,105,12870,DB01026,Ketoconazole
,12235265,T(max),Median T(max) (1.5-2 h) was unchanged.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),h,1.5-2,12871,DB01026,Ketoconazole
,12235265,IC(50),"Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC(50) of 0.625 to 1.25 microM (cyclosporine caused >80% inhibition at 5 microM).",Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),μM,0.625 to 1.25,12872,DB01026,Ketoconazole
,3950868,clearance,"In the presence of ketoconazole, cyclosporine clearance decreased from 15.4 to 7.6 ml/hr; terminal half-life increased from 4.1 to 11.2 hr; and steady-state volume of distribution did not change significantly.",Ketoconazole inhibits cyclosporine metabolism in vivo in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950868/),[ml] / [h],15.4 to 7.6,13193,DB01026,Ketoconazole
,3950868,terminal half-life,"In the presence of ketoconazole, cyclosporine clearance decreased from 15.4 to 7.6 ml/hr; terminal half-life increased from 4.1 to 11.2 hr; and steady-state volume of distribution did not change significantly.",Ketoconazole inhibits cyclosporine metabolism in vivo in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950868/),h,4.1 to 11.2,13194,DB01026,Ketoconazole
,19740395,C(max),"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[ng] / [ml],285,15301,DB01026,Ketoconazole
,19740395,C(max),"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[ng] / [ml],678,15302,DB01026,Ketoconazole
,19740395,AUC,"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[h·ng] / [ml],1666,15303,DB01026,Ketoconazole
,19740395,AUC,"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[h·ng] / [ml],7378,15304,DB01026,Ketoconazole
,19740395,half-life,Sotrastaurin half-life was nearly doubled from 5.9 +/- 1.7 to 10.6 +/- 2.5 h.,The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),h,5.9,15305,DB01026,Ketoconazole
,19740395,half-life,Sotrastaurin half-life was nearly doubled from 5.9 +/- 1.7 to 10.6 +/- 2.5 h.,The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),h,10.6,15306,DB01026,Ketoconazole
,28603935,bioavailability,Oral tramadol bioavailability was low (2.6%).,The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,2.6,15349,DB01026,Ketoconazole
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,18.2,15350,DB01026,Ketoconazole
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,20.3,15351,DB01026,Ketoconazole
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[ng] / [ml],22.9,15352,DB01026,Ketoconazole
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],109.9,15353,DB01026,Ketoconazole
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],143.2,15354,DB01026,Ketoconazole
,28603935,minimum concentration,"However, measured tramadol plasma concentrations were below the minimum concentration considered effective in humans (228 μg/ml).",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],228,15355,DB01026,Ketoconazole
,19246732,half-life (t(1/2),Some investigators suggest that a single dose of 400 mg (SD400) KTZ is sufficient given its short half-life (t(1/2) approximately 3-5 hr).,Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246732/),h,3-5,16567,DB01026,Ketoconazole
,10383565,50% inhibitory concentration (IC50 ),"Ketoconazole had a 50% inhibitory concentration (IC50 ) of 0.61 microm vs formation of the M-3 metabolite of zolpidem in vitro; in a clinical study, ketoconazole coadministration reduced zolpidem oral clearance by approximately 40%, somewhat less than anticipated based on the IC50 value and total plasma ketoconazole levels, but much more than predicted based on unbound plasma ketoconazole levels.","Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383565/),μm,0.61,18082,DB01026,Ketoconazole
,31028057,IC50,"Compared with vehicle, indinavir (10 μM) inhibited midazolam 1'-hydroxylation by recombinant CYP3A4, human liver microsomes, and high-CYP3A activity cryopreserved human hepatocytes by ≥70%; the IC50 obtained with hepatocytes (2.7 μM) was within reported human unbound indinavir Cmax (≤5 μM).",Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028057/),μM,2.7,20008,DB01026,Ketoconazole
≤,31028057,Cmax,"Compared with vehicle, indinavir (10 μM) inhibited midazolam 1'-hydroxylation by recombinant CYP3A4, human liver microsomes, and high-CYP3A activity cryopreserved human hepatocytes by ≥70%; the IC50 obtained with hepatocytes (2.7 μM) was within reported human unbound indinavir Cmax (≤5 μM).",Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028057/),μM,5,20009,DB01026,Ketoconazole
,21075975,IC(50),"In addition, P-gp-mediated digoxin transport was inhibited in a concentration-dependent manner by AZD5672 (IC(50) = 32 μM).",The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21075975/),μM,32,21102,DB01026,Ketoconazole
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],9.5,21772,DB01026,Ketoconazole
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],8.4,21773,DB01026,Ketoconazole
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],135.2,21774,DB01026,Ketoconazole
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],118.7,21775,DB01026,Ketoconazole
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],37.7,21776,DB01026,Ketoconazole
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],27.6,21777,DB01026,Ketoconazole
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],680.9,21778,DB01026,Ketoconazole
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],501.0,21779,DB01026,Ketoconazole
,1681649,Plasma levels,Plasma levels range between 0.1 and 1.0 micrograms/ml.,"Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681649/),[μg] / [ml],0.1 and 1.0,22112,DB01026,Ketoconazole
,1681649,half-life,Elimination of drug from tissue occurs with a half-life of 4 to 5 days and with the potential for drug levels above fungicidal concentrations for dermatophytes for more than 3 weeks.,"Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681649/),d,4 to 5,22113,DB01026,Ketoconazole
,32595511,S/P ratio,"Fluconazole and voriconazole demonstrated a good saliva penetration with an average S/P ratio of 1.21 (± 0.31) for fluconazole and 0.56 (± 0.18) for voriconazole, both with strong correlation (r = 0.89-0.98).",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,1.21,25178,DB01026,Ketoconazole
,32595511,S/P ratio,"Fluconazole and voriconazole demonstrated a good saliva penetration with an average S/P ratio of 1.21 (± 0.31) for fluconazole and 0.56 (± 0.18) for voriconazole, both with strong correlation (r = 0.89-0.98).",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,0.56,25179,DB01026,Ketoconazole
,32595511,clearance,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),[l] / [h],4.56,25180,DB01026,Ketoconazole
,32595511,volume of distribution,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),l,60.7,25181,DB01026,Ketoconazole
,32595511,absorption rate constant,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,0.858,25182,DB01026,Ketoconazole
,32595511,bioavailability,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,0.849,25183,DB01026,Ketoconazole
,30747023,total radioactivity,The total radioactivity recovered in urine and faeces was 89.0% of the administered dose.,"Human mass balance, pharmacokinetics and metabolism of rovatirelin and identification of its metabolic enzymes in vitro. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747023/),%,89.0,26148,DB01026,Ketoconazole
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],659.8,27752,DB01026,Ketoconazole
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],878.1,27753,DB01026,Ketoconazole
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],1125.2,27754,DB01026,Ketoconazole
,24417786,Cmax,"The Cmax of CG100649 with CG100649 only and with concurrent administration of CG100649 + ketoconazole were similar (10.7 and 11.0 ng/mL, respectively).","Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[ng] / [ml],10.7,28111,DB01026,Ketoconazole
,24417786,Cmax,"The Cmax of CG100649 with CG100649 only and with concurrent administration of CG100649 + ketoconazole were similar (10.7 and 11.0 ng/mL, respectively).","Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[ng] / [ml],11.0,28112,DB01026,Ketoconazole
,24417786,AUClast,The CG100649 AUClast with concurrent ketoconazole was 1.29-fold greater than that with CG100649 only (2074.0 and 2685.8 ng · h/mL) and demonstrated a statistically significant difference (P < 0.05).,"Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[h·ng] / [ml],2074.0,28113,DB01026,Ketoconazole
,24417786,AUClast,The CG100649 AUClast with concurrent ketoconazole was 1.29-fold greater than that with CG100649 only (2074.0 and 2685.8 ng · h/mL) and demonstrated a statistically significant difference (P < 0.05).,"Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[h·ng] / [ml],2685.8,28114,DB01026,Ketoconazole
,8591650,bio-availability,This drug's bio-availability averages 25-35% but is highly variable.,"Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),%,25-35,29074,DB01026,Ketoconazole
,8591650,elimination half-life,CSA is metabolized to numerous metabolites by the liver and its elimination half-life is 6-12 hours in the absence of severe liver disease.,"Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),h,6-12,29075,DB01026,Ketoconazole
,8591650,elimination half-life,"Its active metabolite is excreted renally to a large degree, with a prolonged elimination half-life of about 11 days.","Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),d,11,29076,DB01026,Ketoconazole
,20375180,"apparent Michaelis-Menten constant (K(m, app))","The sulfoxidation kinetics characterized in rat, dog, and human liver microsomes (HLM) indicated a low apparent Michaelis-Menten constant (K(m, app)) of 4 to 5 microM.","In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375180/),μM,4 to 5,31924,DB01026,Ketoconazole
,20375180,IC(50),"A subsequent in vitro study using ketoconazole as an inhibitor of CJ-13,610 sulfoxidation corroborated the CYP3A4/5-mediated pathway (IC(50) = 7 nM).","In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375180/),nM,7,31925,DB01026,Ketoconazole
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·ng] / [ml],320 to 740,33690,DB01026,Ketoconazole
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·ng] / [ml],331 to 501,33691,DB01026,Ketoconazole
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·μg] / [ml],207 to 333,33692,DB01026,Ketoconazole
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,2.5,33693,DB01026,Ketoconazole
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,1.9,33694,DB01026,Ketoconazole
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,3.1,33695,DB01026,Ketoconazole
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,2.1,33696,DB01026,Ketoconazole
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,88,33697,DB01026,Ketoconazole
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,95,33698,DB01026,Ketoconazole
,10952769,Ki,"When triazolam is the P450 3A4 substrate and ketoconazole the competitive inhibitor, Ki approximately 1.2 microg/mL in humans.",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),[μg] / [ml],1.2,34568,DB01026,Ketoconazole
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,95,34569,DB01026,Ketoconazole
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,35,34570,DB01026,Ketoconazole
,27490210,CmaxCF/CmaxEF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,4.41,36577,DB01026,Ketoconazole
,27490210,CmaxCF/CmaxEF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,0,36578,DB01026,Ketoconazole
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,3.69,36579,DB01026,Ketoconazole
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,1.84,36580,DB01026,Ketoconazole
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,1.76,36581,DB01026,Ketoconazole
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,26.57,36582,DB01026,Ketoconazole
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,27.45,36583,DB01026,Ketoconazole
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,30.88,36584,DB01026,Ketoconazole
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,5.79,36585,DB01026,Ketoconazole
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,35.18,36586,DB01026,Ketoconazole
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,38.11,36587,DB01026,Ketoconazole
,9757147,clearance,"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],27,38781,DB01026,Ketoconazole
,9757147,clearance,"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],86,38782,DB01026,Ketoconazole
,9757147,apparent elimination half-life (t1/2),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,59,38783,DB01026,Ketoconazole
,9757147,apparent elimination half-life (t1/2),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,15,38784,DB01026,Ketoconazole
,9757147,peak plasma concentration (Cmax),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],16.1,38785,DB01026,Ketoconazole
,9757147,peak plasma concentration (Cmax),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],14.7,38786,DB01026,Ketoconazole
,9757147,clearance,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],40,38787,DB01026,Ketoconazole
,9757147,clearance,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],444,38788,DB01026,Ketoconazole
,9757147,t1/2,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,18.3,38789,DB01026,Ketoconazole
,9757147,t1/2,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,3.0,38790,DB01026,Ketoconazole
,9757147,Cmax,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],2.6,38791,DB01026,Ketoconazole
,9757147,Cmax,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],5.4,38792,DB01026,Ketoconazole
,10771458,"AUC(0,infinity)","Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[h·ng] / [ml],899,39121,DB01026,Ketoconazole
,10771458,"AUC(0,infinity)","Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[h·ng] / [ml],1199,39122,DB01026,Ketoconazole
,10771458,Cmax,"Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[ng] / [ml],89,39123,DB01026,Ketoconazole
,10771458,Cmax,"Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[ng] / [ml],119,39124,DB01026,Ketoconazole
,20472816,bioavailability,"It has an approximately 15% bioavailability, with plasma concentrations markedly increasing after a high-fat meal; it is recommended to be taken with food.",Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472816/),%,15,40252,DB01026,Ketoconazole
,20472816,half-life,The primary metabolic clearance pathway for dronedarone is via the hepatic enzyme system (primarily cytochrome P450 3A4 [CYP3A4]); the half-life of dronedarone is 27 to 31 hours.,Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472816/),h,27 to 31,40253,DB01026,Ketoconazole
,11744613,K(i),"The K(i) values of KTZ for MDZ 1'-hydroxylation and 4-hydroxylation were 0.0237 and 0.111 microM, respectively, indicating that KTZ extensively inhibits hepatic CYP3A activity in dogs.","Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744613/),μM,0.0237,40339,DB01026,Ketoconazole
,11744613,K(i),"The K(i) values of KTZ for MDZ 1'-hydroxylation and 4-hydroxylation were 0.0237 and 0.111 microM, respectively, indicating that KTZ extensively inhibits hepatic CYP3A activity in dogs.","Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744613/),μM,0.111,40340,DB01026,Ketoconazole
,12369444,absolute bioavailability,The substance has an absolute bioavailability upon oral administration of approximately 52% which is robust against food intake or administration of antacids.,Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369444/),%,52,41783,DB01026,Ketoconazole
,12369444,Elimination half-life,Elimination half-life is about 1 h.,Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369444/),h,1,41784,DB01026,Ketoconazole
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],96,42037,DB01026,Ketoconazole
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],90,42038,DB01026,Ketoconazole
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.29,42039,DB01026,Ketoconazole
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.45,42040,DB01026,Ketoconazole
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.41,42041,DB01026,Ketoconazole
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.40,42042,DB01026,Ketoconazole
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,0.127,43675,DB01026,Ketoconazole
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,94.2,43676,DB01026,Ketoconazole
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,29.6,43677,DB01026,Ketoconazole
,16628140,CL,"Midazolam CL were normally distributed in both groups, and ranged from 1.7 to 51.9 and 1.4 to 8.2 L/hour in the control and ketoconazole groups, respectively, corresponding to a 7-fold reduction in dispersion between the 2 groups.",Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628140/),[l] / [h],1.7 to 51.9,43995,DB01026,Ketoconazole
,16628140,CL,"Midazolam CL were normally distributed in both groups, and ranged from 1.7 to 51.9 and 1.4 to 8.2 L/hour in the control and ketoconazole groups, respectively, corresponding to a 7-fold reduction in dispersion between the 2 groups.",Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628140/),[l] / [h],1.4 to 8.2,43996,DB01026,Ketoconazole
,30052328,half-life,Maximum alicapistat plasma concentrations were reached in 2 to 5 hours; half-life was 7 to 12 hours postdose.,"Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30052328/),h,7 to 12,44852,DB01026,Ketoconazole
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,18.37,45135,DB01026,Ketoconazole
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,26.08,45136,DB01026,Ketoconazole
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,8.68,45137,DB01026,Ketoconazole
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,22.67,45138,DB01026,Ketoconazole
,7711339,peak salivary concentration,The mean (+/- SD) peak salivary concentration for ketoconazole was 0.119 +/- 0.050 microgram/mL at 3 hours; no subject had a detectable ketoconazole salivary concentration at 24 hours.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.119,45504,DB01026,Ketoconazole
,7711339,plasma concentrations,"At 2 and 24 hours, mean ketoconazole plasma concentrations were 7.64 +/- 3.87 and 0.11 +/- 0.05 microgram/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],7.64,45505,DB01026,Ketoconazole
,7711339,plasma concentrations,"At 2 and 24 hours, mean ketoconazole plasma concentrations were 7.64 +/- 3.87 and 0.11 +/- 0.05 microgram/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.11,45506,DB01026,Ketoconazole
,7711339,saliva to plasma concentration ratio,The saliva to plasma concentration ratio at 2 hours was 0.01.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),,0.01,45507,DB01026,Ketoconazole
,7711339,peak salivary concentration,The mean peak salivary concentration of fluconazole was 2.56 +/- 0.34 microgram/mL at 3 hours.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],2.56,45508,DB01026,Ketoconazole
,7711339,salivary concentration,"At 24 hours, the mean salivary concentration was 1.44 +/- 0.33 microgram/mL.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],1.44,45509,DB01026,Ketoconazole
,7711339,plasma concentrations,"At 2 and 24 hours, mean fluconazole plasma concentrations were 4.39 +/- 3.33 and 3.72 +/- 2.83 micrograms/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],4.39,45510,DB01026,Ketoconazole
,7711339,plasma concentrations,"At 2 and 24 hours, mean fluconazole plasma concentrations were 4.39 +/- 3.33 and 3.72 +/- 2.83 micrograms/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],3.72,45511,DB01026,Ketoconazole
,7711339,saliva to plasma concentration ratio,The saliva to plasma concentration ratio at 2 hours was 0.55.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),,0.55,45512,DB01026,Ketoconazole
,7711339,MIC,Median MIC values were 0.0625 microgram/mL (range 0.0313-0.125) for ketoconazole and 0.25 microgram/mL (range 0.125-0.5) for fluconazole.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.0625,45513,DB01026,Ketoconazole
,7711339,MIC,Median MIC values were 0.0625 microgram/mL (range 0.0313-0.125) for ketoconazole and 0.25 microgram/mL (range 0.125-0.5) for fluconazole.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.25,45514,DB01026,Ketoconazole
,7711339,MICs,"Calculated times over which ketoconazole and fluconazole exceeded the median MICs in saliva were approximately 13 and greater than 24 hours, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),h,13,45515,DB01026,Ketoconazole
greater,7711339,MICs,"Calculated times over which ketoconazole and fluconazole exceeded the median MICs in saliva were approximately 13 and greater than 24 hours, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),h,24,45516,DB01026,Ketoconazole
,9654217,AUC,"When given intravenously, digoxin AUC increased from 93 +/- 22 to 486 +/- 26 microg x h/l with ketoconazole administration.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],93,46037,DB01026,Ketoconazole
,9654217,AUC,"When given intravenously, digoxin AUC increased from 93 +/- 22 to 486 +/- 26 microg x h/l with ketoconazole administration.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],486,46038,DB01026,Ketoconazole
,9654217,AUC,"Similarly, ketoconazole raised the AUC of orally administered digoxin from 63 +/- 17 to 411 +/- 50 microg x h/l.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],63,46039,DB01026,Ketoconazole
,9654217,AUC,"Similarly, ketoconazole raised the AUC of orally administered digoxin from 63 +/- 17 to 411 +/- 50 microg x h/l.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],411,46040,DB01026,Ketoconazole
,9654217,bioavailability,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),,0.68,46041,DB01026,Ketoconazole
,9654217,bioavailability,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),,0.84,46042,DB01026,Ketoconazole
,9654217,mean absorption time,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),h,1.1,46043,DB01026,Ketoconazole
,9654217,mean absorption time,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),h,0.3,46044,DB01026,Ketoconazole
,25851638,absolute bioavailability,"Tasimelteon is rapidly absorbed, with a mean absolute bioavailability of approximately 38%, and is extensively metabolized primarily by oxidation at multiple sites, mainly by cytochrome P450 (CYP) 1A2 and CYP3A4/5, as initially demonstrated by in vitro studies and confirmed by the results of clinical drug-drug interactions presented here.","Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851638/),%,38,47044,DB01026,Ketoconazole
,10417494,inlet concentration,"The inlet concentration of (R/S)-verapamil was 120 mg l-1 in both periods, and ketoconazole was added at 40 mg l-1 in period 2.",The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417494/),[mg] / [l],120,49074,DB01026,Ketoconazole
,25450725,fraction absorbed,"The fraction absorbed and intestinal availability of teneligliptin predicted by the model were 0.62 and 0.99, respectively.",Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25450725/),,0,50163,DB01026,Ketoconazole
,15496339,retention times,"The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively.",LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),min,1.2,51495,DB01026,Ketoconazole
,15496339,retention times,"The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively.",LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),min,0.8,51496,DB01026,Ketoconazole
,15496339,area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),[h·ng] / [ml],19.26,51497,DB01026,Ketoconazole
,15496339,peak plasma concentration (Cmax),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),[ng] / [ml],1.18,51498,DB01026,Ketoconazole
,15496339,time to Cmax (Tmax),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),h,5.38,51499,DB01026,Ketoconazole
,15496339,elimination half-life (t1/2),The following pharmacokinetic parameters were elucidated after administering a single dose of four 2mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC72 h) 19.26 +/- 7.79 ng h/ml; peak plasma concentration (Cmax) 1.18 +/- 0.37 ng/ml; time to Cmax (Tmax) 5.38 +/- 0.74 h; and elimination half-life (t1/2) 11.35 +/- 2.06 h.,LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496339/),h,11.35,51500,DB01026,Ketoconazole
,10092957,alpha,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),min,4.5,52392,DB01026,Ketoconazole
,10092957,beta,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),min,38.3,52393,DB01026,Ketoconazole
,10092957,gamma half-lives,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),h,12.2,52394,DB01026,Ketoconazole
,10092957,volume of distribution,"Docetaxel is widely distributed in tissues with a mean volume of distribution of 74 L/m2 after 100 mg/m2, every 3 weeks.",Clinical pharmacokinetics of docetaxel. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),[l] / [m2],74,52395,DB01026,Ketoconazole
,10092957,total body clearance,"The mean total body clearance after this schedule is approximately 22 L/h/m2, principally because of hepatic metabolism by the cytochrome P450 (CYP)3A4 system and biliary excretion into the faeces.",Clinical pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),[l] / [h·m2],22,52396,DB01026,Ketoconazole
<,10092957,Renal excretion,Renal excretion is minimal (< 5%).,Clinical pharmacokinetics of docetaxel. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),%,5,52397,DB01026,Ketoconazole
,1994529,trough whole-blood,"The mean trough whole-blood cyclosporine concentrations measured by HPLC, were 130 ng/mL preketoconazole and 149 ng/mL after 1 year of combination therapy.",Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1994529/),[ng] / [ml],130,52439,DB01026,Ketoconazole
,1994529,trough whole-blood,"The mean trough whole-blood cyclosporine concentrations measured by HPLC, were 130 ng/mL preketoconazole and 149 ng/mL after 1 year of combination therapy.",Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1994529/),[ng] / [ml],149,52440,DB01026,Ketoconazole
,18447799,half-life,Morphine was rapidly eliminated with a half-life of 1.28 hours and a plasma clearance of 32.55 mL/min/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),h,1.28,52879,DB01026,Ketoconazole
,18447799,plasma clearance,Morphine was rapidly eliminated with a half-life of 1.28 hours and a plasma clearance of 32.55 mL/min/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),[ml] / [kg·min],32.55,52880,DB01026,Ketoconazole
,18447799,volume of distribution,The volume of distribution was 3.6 L/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),[l] / [kg],3.6,52881,DB01026,Ketoconazole
,18784280,K(m),Aliskiren stimulated in vitro P-glycoprotein ATPase activity in recombinant baculovirus-infected Sf9 cells with high affinity (K(m) 2.1 micromol/L) and was transported by organic anion-transporting peptide OATP2B1-expressing HEK293 cells with moderate affinity (K(m) 72 micromol/L).,"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18784280/),[μM] / [l],2.1,54148,DB01026,Ketoconazole
,18784280,K(m),Aliskiren stimulated in vitro P-glycoprotein ATPase activity in recombinant baculovirus-infected Sf9 cells with high affinity (K(m) 2.1 micromol/L) and was transported by organic anion-transporting peptide OATP2B1-expressing HEK293 cells with moderate affinity (K(m) 72 micromol/L).,"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18784280/),[μM] / [l],72,54149,DB01026,Ketoconazole
<,7808019,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808019/),h,1,54541,DB01026,Ketoconazole
,7808019,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808019/),h,13,54542,DB01026,Ketoconazole
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,5,56069,DB01026,Ketoconazole
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,0.4,56070,DB01026,Ketoconazole
,9246018,clearance,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[ml] / [h·kg],55.6,56123,DB01026,Ketoconazole
,9246018,clearance,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[ml] / [h·kg],42.5,56124,DB01026,Ketoconazole
,9246018,steady-state volume of distribution,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[l] / [kg],0.99,56125,DB01026,Ketoconazole
,9246018,steady-state volume of distribution,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[l] / [kg],0.93,56126,DB01026,Ketoconazole
,9246018,bioavailability,"However, a significant increase in tacrolimus bioavailability (14% +/- 5% versus 30% +/- 8%; p < 0.01) was observed with coadministered ketoconazole.",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,14,56127,DB01026,Ketoconazole
,9246018,bioavailability,"However, a significant increase in tacrolimus bioavailability (14% +/- 5% versus 30% +/- 8%; p < 0.01) was observed with coadministered ketoconazole.",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,30,56128,DB01026,Ketoconazole
,9246018,Hepatic bioavailability,Hepatic bioavailability was unchanged by the presence of ketoconazole (96% +/- 1% versus 97% +/- 1%).,Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,96,56129,DB01026,Ketoconazole
,9246018,Hepatic bioavailability,Hepatic bioavailability was unchanged by the presence of ketoconazole (96% +/- 1% versus 97% +/- 1%).,Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,97,56130,DB01026,Ketoconazole
,20740300,C(max),"For axitinib alone or with ketoconazole, C(max) occurred 1.5 and 2.0 h after dosing, respectively.",Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740300/),h,1.5,57005,DB01026,Ketoconazole
,20740300,C(max),"For axitinib alone or with ketoconazole, C(max) occurred 1.5 and 2.0 h after dosing, respectively.",Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740300/),h,2.0,57006,DB01026,Ketoconazole
,16584282,terminal elimination half-life,Darifenacin was found to have a short terminal elimination half-life after intravenous and immediate-release oral dosage forms (3-4 hours) but this increased with a prolonged-release (PR) formulation (14-16 hours).,The clinical pharmacokinetics of darifenacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),h,3-4,57262,DB01026,Ketoconazole
,16584282,terminal elimination half-life,Darifenacin was found to have a short terminal elimination half-life after intravenous and immediate-release oral dosage forms (3-4 hours) but this increased with a prolonged-release (PR) formulation (14-16 hours).,The clinical pharmacokinetics of darifenacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),h,14-16,57263,DB01026,Ketoconazole
,16584282,absolute bioavailability,"The absolute bioavailability of darifenacin from 7.5 and 15 mg PR tablets was estimated to be 15.4% and 18.6%, respectively.",The clinical pharmacokinetics of darifenacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),%,15.4,57264,DB01026,Ketoconazole
,16584282,absolute bioavailability,"The absolute bioavailability of darifenacin from 7.5 and 15 mg PR tablets was estimated to be 15.4% and 18.6%, respectively.",The clinical pharmacokinetics of darifenacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),%,18.6,57265,DB01026,Ketoconazole
,16584282,plasma clearance,"From intravenous administration, it has been established that darifenacin possesses a moderate-to-high hepatic extraction ratio, with high plasma clearance (36-52 L/h) and a volume of distribution (165-276L) that exceeds total body water.",The clinical pharmacokinetics of darifenacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),[l] / [h],36-52,57266,DB01026,Ketoconazole
,16584282,volume of distribution,"From intravenous administration, it has been established that darifenacin possesses a moderate-to-high hepatic extraction ratio, with high plasma clearance (36-52 L/h) and a volume of distribution (165-276L) that exceeds total body water.",The clinical pharmacokinetics of darifenacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),l,165-276,57267,DB01026,Ketoconazole
,20864622,AUC ratio,"The mean simulated degree of interaction, measured by midazolam AUC ratio with and without ketoconazole (AUCR), was 10.28.",Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20864622/),,10.28,59097,DB01026,Ketoconazole
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,21.5,59195,DB01026,Ketoconazole
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,18.9,59196,DB01026,Ketoconazole
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.8,59197,DB01026,Ketoconazole
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.4,59198,DB01026,Ketoconazole
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.76,59199,DB01026,Ketoconazole
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.39,59200,DB01026,Ketoconazole
less,3027850,MICs,"The MICs of itraconazole for 16 strains of Aspergillus fumigatus were in the same range as those of amphotericin B: less than 0.09-0.36 microgram/ml vs. less than 0.09-0.78 microgram/ml, respectively.",Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3027850/),[μg] / [ml],0.09-0.36,61359,DB01026,Ketoconazole
less,3027850,MICs,"The MICs of itraconazole for 16 strains of Aspergillus fumigatus were in the same range as those of amphotericin B: less than 0.09-0.36 microgram/ml vs. less than 0.09-0.78 microgram/ml, respectively.",Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3027850/),[μg] / [ml],0.09-0.78,61360,DB01026,Ketoconazole
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],5.5,61646,DB01026,Ketoconazole
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],171.9,61647,DB01026,Ketoconazole
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],13.1,61648,DB01026,Ketoconazole
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],3075.2,61649,DB01026,Ketoconazole
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,11,63198,DB01026,Ketoconazole
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,83,63199,DB01026,Ketoconazole
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,24,63200,DB01026,Ketoconazole
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,20,63201,DB01026,Ketoconazole
,7946933,liver:water partition ratios,"4. The in vitro data predict 29% inhibition of ALP clearance at mean FLU and NOR plasma concentrations of 77 ng ml-1 and 72 ng ml-1, respectively, after correction for liver:water partition ratios in the range of 12-14.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),,12-14,63202,DB01026,Ketoconazole
,7946933,Ki,"5. Ketoconazole was a potent inhibitor of ALP metabolism in vitro (Ki = 0.046 microM), suggesting that ALP hydroxylation is mediated by the cytochrome P450-3A sub-family.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,0.046,63203,DB01026,Ketoconazole
,7946933,Ki,Quinidine was a weak inhibitor (Ki = 626 microM).,"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,626,63204,DB01026,Ketoconazole
,11466177,flow rate,"The internal standard and glyburide eluted at about 6.7 and 9.6 min, respectively at the flow rate of 1 mL/min.",A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),[ml] / [min],1,64264,DB01026,Ketoconazole
,11466177,absolute recovery,The absolute recovery ranged from 94.32 to 98.12% and the relative recovery ranged from 91.12 to 97.15%.,A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),%,94.32 to 98.12,64265,DB01026,Ketoconazole
,11466177,relative recovery,The absolute recovery ranged from 94.32 to 98.12% and the relative recovery ranged from 91.12 to 97.15%.,A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),%,91.12 to 97.15,64266,DB01026,Ketoconazole
,10993198,Ki,"The Ki values of KCZ and FCZ for NVP 12-hydroxylation were 1.59 microm and 11.5 microM, respectively, indicating that KCZ inhibited this activity more strongly than FCZ in vitro.",Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993198/),μm,1.59,66283,DB01026,Ketoconazole
,10993198,Ki,"The Ki values of KCZ and FCZ for NVP 12-hydroxylation were 1.59 microm and 11.5 microM, respectively, indicating that KCZ inhibited this activity more strongly than FCZ in vitro.",Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993198/),μM,11.5,66284,DB01026,Ketoconazole
,10993198,unbound fraction,"Further, the unbound fraction of KCZ was decreased dramatically to around 3%, whereas more than 90% of FCZ remained in unbound form.",Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993198/),%,3,66285,DB01026,Ketoconazole
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.037,66325,DB01026,Ketoconazole
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.34,66326,DB01026,Ketoconazole
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.28,66327,DB01026,Ketoconazole
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,2.05,66328,DB01026,Ketoconazole
,22210483,IC(50),"Efonidipine inhibited CYP3A4 activity with an IC(50) value of 0.08 μM, and efonidipine significantly inhibited P-gp activity in a concentration-dependent manner.",Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210483/),μM,0.08,68078,DB01026,Ketoconazole
,22210483,absolute bioavailability,Efonidipine also significantly (P < 0.01 for 3 mg/kg) increased the absolute bioavailability (AB) of repaglinide by 51.5% compared to the oral control group (33.6%).,Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210483/),%,33.6,68079,DB01026,Ketoconazole
,23401471,Michaelis-Menten constant (Km),"The Michaelis-Menten constant (Km) values of hepatic microsomal metabolism were 7.23 and 0.41 μM in rats and dogs in vitro, respectively, which were lower than the unbound maximum plasma concentrations after oral administration in vivo, indicating that the nonlinear PK in rats and dogs was attributable to the saturation of hepatic metabolism.","Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23401471/),μM,7.23,68197,DB01026,Ketoconazole
,23401471,Michaelis-Menten constant (Km),"The Michaelis-Menten constant (Km) values of hepatic microsomal metabolism were 7.23 and 0.41 μM in rats and dogs in vitro, respectively, which were lower than the unbound maximum plasma concentrations after oral administration in vivo, indicating that the nonlinear PK in rats and dogs was attributable to the saturation of hepatic metabolism.","Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23401471/),μM,0.41,68198,DB01026,Ketoconazole
,23401471,Km,"However, we do not believe that the saturation of hepatic metabolism was the mechanism of nonlinearity in monkeys because of the high Km value (42.44 μM) observed in liver microsomes.","Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23401471/),μM,42.44,68199,DB01026,Ketoconazole
,9262358,Km1,"The metabolism of YM796 was shown to consist of three components; one high-affinity (Km1 = 1.67 microM), one low-affinity (Km2 = 654 microM) and a nonsaturable component.",Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262358/),μM,1.67,68213,DB01026,Ketoconazole
,9262358,Km2,"The metabolism of YM796 was shown to consist of three components; one high-affinity (Km1 = 1.67 microM), one low-affinity (Km2 = 654 microM) and a nonsaturable component.",Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262358/),μM,654,68214,DB01026,Ketoconazole
,27379747,flow rate,The flow rate was 0.5mL/min.,A highly sensitive LC-MS/MS method for determination of ketoconazole in human plasma: Application to a clinical study of the exposure to ketoconazole in patients after topical administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379747/),[ml] / [min],0.5,68987,DB01026,Ketoconazole
,28575987,AUC(0-t),In vivo skin deposition parameters further confirmed high skin deposition of drug-loaded micelles (AUC(0-t)=396.16μg·h/cm2) over marketed ketoconazole cream (AUC(0-t)=250.03μg·h/cm2).,Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [cm2],396.16,69719,DB01026,Ketoconazole
,28575987,AUC(0-t),In vivo skin deposition parameters further confirmed high skin deposition of drug-loaded micelles (AUC(0-t)=396.16μg·h/cm2) over marketed ketoconazole cream (AUC(0-t)=250.03μg·h/cm2).,Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [cm2],250.03,69720,DB01026,Ketoconazole
,28575987,AUC(0-t),"Meanwhile, in vivo pharmacokinetic parameters proved that ketoconazole-loaded micelles reduced ketoconazole's distribution in blood in comparison with the cream (AUC(0-t)=93,028.00μg·h/L vs AUC(0-t)=151,714.00μg·h/L), meaning lower possibility of its systemic unwanted effects in the skin fungal infection treatment.",Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [l],"93,028.00",69721,DB01026,Ketoconazole
,28575987,AUC(0-t),"Meanwhile, in vivo pharmacokinetic parameters proved that ketoconazole-loaded micelles reduced ketoconazole's distribution in blood in comparison with the cream (AUC(0-t)=93,028.00μg·h/L vs AUC(0-t)=151,714.00μg·h/L), meaning lower possibility of its systemic unwanted effects in the skin fungal infection treatment.",Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [l],"151,714.00",69722,DB01026,Ketoconazole
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],160,69779,DB01026,Ketoconazole
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],148,69780,DB01026,Ketoconazole
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,5.03,69781,DB01026,Ketoconazole
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,6.18,69782,DB01026,Ketoconazole
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.23,69783,DB01026,Ketoconazole
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.19,69784,DB01026,Ketoconazole
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.79,69785,DB01026,Ketoconazole
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.84,69786,DB01026,Ketoconazole
,9871431,apparent oral clearance,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],422,71084,DB01026,Ketoconazole
,9871431,elimination half-life,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,1.9,71085,DB01026,Ketoconazole
,9871431,Clearance,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],250,71086,DB01026,Ketoconazole
,9871431,half-life,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,2.4,71087,DB01026,Ketoconazole
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],320,71088,DB01026,Ketoconazole
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],338,71089,DB01026,Ketoconazole
,28128722,CL/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),[l] / [h],9.16,71715,DB01026,Ketoconazole
,28128722,V2/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),l,34.3,71716,DB01026,Ketoconazole
,28128722,Q/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),[l] / [h],16.4,71717,DB01026,Ketoconazole
,28128722,V3/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),l,250,71718,DB01026,Ketoconazole
,28128722,ka,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),1/[h<sup>·sup>],0.522,71719,DB01026,Ketoconazole
,14656603,flow rate,"Mobile phase consisting of sodium dihydrogen phosphate monohydrate (pH 4.5, 0.02 M) and methanol mixture (35:65, v/v) was used at a flow rate of 1.0 ml/min.","Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14656603/),[ml] / [min],1.0,72168,DB01026,Ketoconazole
,14656603,retention times,"The retention times of LASSBio-581 and the internal standard were approximately 3.8 and 5.6 min, respectively.","Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14656603/),min,3.8,72169,DB01026,Ketoconazole
,14656603,retention times,"The retention times of LASSBio-581 and the internal standard were approximately 3.8 and 5.6 min, respectively.","Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14656603/),min,5.6,72170,DB01026,Ketoconazole
,9987703,terminal half-life,"The mean terminal half-life was approximately 45 and 44 hours, respectively.",Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987703/),h,45,72608,DB01026,Ketoconazole
,9987703,terminal half-life,"The mean terminal half-life was approximately 45 and 44 hours, respectively.",Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987703/),h,44,72609,DB01026,Ketoconazole
,18651556,bioavailability,"Thus, the bioavailability of TAK-427 after oral administration in rats (7.3%) markedly increased when co-administered with P-gp inhibitors (28.6-57.6%).",Marked impact of P-glycoprotein on the absorption of TAK-427 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651556/),%,7.3,73314,DB01026,Ketoconazole
,18651556,bioavailability,"Thus, the bioavailability of TAK-427 after oral administration in rats (7.3%) markedly increased when co-administered with P-gp inhibitors (28.6-57.6%).",Marked impact of P-glycoprotein on the absorption of TAK-427 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651556/),%,28.6-57.6,73315,DB01026,Ketoconazole
,15568889,absolute bioavailability,The absolute bioavailability is about 50%.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),%,50,73755,DB01026,Ketoconazole
,15568889,volume of distribution,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),l,30,73756,DB01026,Ketoconazole
,15568889,clearance,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),[l] / [h],17,73757,DB01026,Ketoconazole
,15568889,terminal half-life,The terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),h,5.4,73758,DB01026,Ketoconazole
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB01026,Ketoconazole
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB01026,Ketoconazole
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB01026,Ketoconazole
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB01026,Ketoconazole
,7738219,inhibition constants (Ki),"Ketoconazole inhibition constants (Ki) averaged 0.024 microM for the desalkyl terfenadine pathway, and 0.237 microM for the hydroxy terfenadine pathway.",In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738219/),μM,0.024,76336,DB01026,Ketoconazole
,7738219,inhibition constants (Ki),"Ketoconazole inhibition constants (Ki) averaged 0.024 microM for the desalkyl terfenadine pathway, and 0.237 microM for the hydroxy terfenadine pathway.",In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738219/),μM,0.237,76337,DB01026,Ketoconazole
,17089336,ratio of intrinsic formation clearances,Formation of (-)-DHF exceeded that of (+)-DHF in liver microsomes [(-):(+) ratio of intrinsic formation clearances = 1.4].,The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: evidence of tissue-specific enantioselectivity in microsomal metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089336/),,1.4,77047,DB01026,Ketoconazole
,33730100,lag phase,The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0-19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1-5.9 pg/h).,The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33730100/),h,18.5,77232,DB01026,Ketoconazole
,33730100,zero-order elimination rate,The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0-19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1-5.9 pg/h).,The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33730100/),[pg] / [h],5.5,77233,DB01026,Ketoconazole
,18021336,area under the curve from time zero to infinity (AUC(0-alpha)),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[h·ng] / [ml],955.94,78698,DB01026,Ketoconazole
,18021336,area under the curve from time zero to infinity (AUC(0-alpha)),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[h·ng] / [ml],1843.10,78699,DB01026,Ketoconazole
,18021336,area under the curve from time zero to infinity (AUC(0-alpha)),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ng] / [ml],183.38,78700,DB01026,Ketoconazole
,18021336,maximum plasma concentration (Cmax),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ng] / [ml],183.38,78701,DB01026,Ketoconazole
,18021336,maximum plasma concentration (Cmax),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ng] / [ml],371.31,78702,DB01026,Ketoconazole
,18021336,total clearance (Cl/F),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ml] / [h·kg],2.65,78703,DB01026,Ketoconazole
,18021336,total clearance (Cl/F),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ml] / [h·kg],1.11,78704,DB01026,Ketoconazole
,18674917,IC(50),"Another rather potent and more selective inhibitor (compound 23, IC(50)=345 nM) was further examined in rats regarding plasma testosterone levels and pharmacokinetic properties.","Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674917/),nM,345,78974,DB01026,Ketoconazole
,18674917,plasma half-life,"Compared to the reference Abiraterone, 23 was more active in vivo, showed a longer plasma half-life (10h) and a higher bioavailability.","Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674917/),h,10,78975,DB01026,Ketoconazole
,13680852,detection limit,The detection limit was of 5.0 microg/L cyclosporin A.,Improvement of cyclosporin A determination in whole blood by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680852/),[μg] / [l],5.0,80321,DB01026,Ketoconazole
,26625716,Cmax,"The Cmax was increased markedly from 59.5 to 78.7 and 131.3ng/mL in case of OA alone, OPCH alone and OPCH with KCZ.","Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26625716/),[ng] / [ml],59.5,81771,DB01026,Ketoconazole
,26625716,Cmax,"The Cmax was increased markedly from 59.5 to 78.7 and 131.3ng/mL in case of OA alone, OPCH alone and OPCH with KCZ.","Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26625716/),[ng] / [ml],78.7,81772,DB01026,Ketoconazole
,26625716,Cmax,"The Cmax was increased markedly from 59.5 to 78.7 and 131.3ng/mL in case of OA alone, OPCH alone and OPCH with KCZ.","Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26625716/),[ng] / [ml],131.3,81773,DB01026,Ketoconazole
,26625716,AUC0-24h,"In parallel with the Cmax, the AUC0-24h was increased from 259.6 to 306.6 and 707.7ngh/mL, respectively.","Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26625716/),[ngh] / [ml],259.6,81774,DB01026,Ketoconazole
,26625716,AUC0-24h,"In parallel with the Cmax, the AUC0-24h was increased from 259.6 to 306.6 and 707.7ngh/mL, respectively.","Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26625716/),[ngh] / [ml],306.6,81775,DB01026,Ketoconazole
,26625716,AUC0-24h,"In parallel with the Cmax, the AUC0-24h was increased from 259.6 to 306.6 and 707.7ngh/mL, respectively.","Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26625716/),[ngh] / [ml],707.7,81776,DB01026,Ketoconazole
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],3.1,82553,DB01026,Ketoconazole
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],7.0,82554,DB01026,Ketoconazole
,2260347,Protein binding,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),%,11,82555,DB01026,Ketoconazole
,2260347,cerebrospinal fluid to serum ratio,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),,0.58 to 0.89,82556,DB01026,Ketoconazole
,2260347,Serum half-life,Serum half-life is long (22-32 hours) and elimination is via renal clearance of unchanged drug.,Fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),h,22-32,82557,DB01026,Ketoconazole
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,13.4,83627,DB01026,Ketoconazole
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,3.4,83628,DB01026,Ketoconazole
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,2.7,83629,DB01026,Ketoconazole
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,3.3,83630,DB01026,Ketoconazole
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,10,83631,DB01026,Ketoconazole
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,13,83632,DB01026,Ketoconazole
,9219927,K(m),"However, the K(m) for the substrate progesterone was lower at 4.3 nM.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,4.3,83633,DB01026,Ketoconazole
,30588869,Cmax,"4. After oral eletriptan in presence of ketoconazole, Cmax (40 vs. 32 ng/mL alone) and AUCinf (81 vs. 24 ng.h/mL alone) of eletriptan increased; the formation of N-desmethyl eletriptan decreased (Cmax=1.1 ng/mL, 3.9%) with ketoconazole as compared to without treatment (Cmax=3.7 ng/mL, 11.2%).",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[ng] / [ml],40,87111,DB01026,Ketoconazole
,30588869,Cmax,"4. After oral eletriptan in presence of ketoconazole, Cmax (40 vs. 32 ng/mL alone) and AUCinf (81 vs. 24 ng.h/mL alone) of eletriptan increased; the formation of N-desmethyl eletriptan decreased (Cmax=1.1 ng/mL, 3.9%) with ketoconazole as compared to without treatment (Cmax=3.7 ng/mL, 11.2%).",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[ng] / [ml],32,87112,DB01026,Ketoconazole
,30588869,AUCinf,"4. After oral eletriptan in presence of ketoconazole, Cmax (40 vs. 32 ng/mL alone) and AUCinf (81 vs. 24 ng.h/mL alone) of eletriptan increased; the formation of N-desmethyl eletriptan decreased (Cmax=1.1 ng/mL, 3.9%) with ketoconazole as compared to without treatment (Cmax=3.7 ng/mL, 11.2%).",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[h·ng] / [ml],81,87113,DB01026,Ketoconazole
,30588869,AUCinf,"4. After oral eletriptan in presence of ketoconazole, Cmax (40 vs. 32 ng/mL alone) and AUCinf (81 vs. 24 ng.h/mL alone) of eletriptan increased; the formation of N-desmethyl eletriptan decreased (Cmax=1.1 ng/mL, 3.9%) with ketoconazole as compared to without treatment (Cmax=3.7 ng/mL, 11.2%).",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[h·ng] / [ml],24,87114,DB01026,Ketoconazole
,30588869,Cmax,"4. After oral eletriptan in presence of ketoconazole, Cmax (40 vs. 32 ng/mL alone) and AUCinf (81 vs. 24 ng.h/mL alone) of eletriptan increased; the formation of N-desmethyl eletriptan decreased (Cmax=1.1 ng/mL, 3.9%) with ketoconazole as compared to without treatment (Cmax=3.7 ng/mL, 11.2%).",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[ng] / [ml],1.1,87115,DB01026,Ketoconazole
,30588869,Cmax,"4. After oral eletriptan in presence of ketoconazole, Cmax (40 vs. 32 ng/mL alone) and AUCinf (81 vs. 24 ng.h/mL alone) of eletriptan increased; the formation of N-desmethyl eletriptan decreased (Cmax=1.1 ng/mL, 3.9%) with ketoconazole as compared to without treatment (Cmax=3.7 ng/mL, 11.2%).",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[ng] / [ml],3.7,87116,DB01026,Ketoconazole
,30588869,Cmax,"After subcutaneous eletriptan in presence of ketoconazole, there was no change in Cmax (153 vs.152 ng/mL) or AUCinf (267 vs. 266 ng.h/mL) of eletriptan.",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[ng] / [ml],153,87117,DB01026,Ketoconazole
,30588869,Cmax,"After subcutaneous eletriptan in presence of ketoconazole, there was no change in Cmax (153 vs.152 ng/mL) or AUCinf (267 vs. 266 ng.h/mL) of eletriptan.",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[ng] / [ml],152,87118,DB01026,Ketoconazole
,30588869,AUCinf,"After subcutaneous eletriptan in presence of ketoconazole, there was no change in Cmax (153 vs.152 ng/mL) or AUCinf (267 vs. 266 ng.h/mL) of eletriptan.",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[h·ng] / [ml],267,87119,DB01026,Ketoconazole
,30588869,AUCinf,"After subcutaneous eletriptan in presence of ketoconazole, there was no change in Cmax (153 vs.152 ng/mL) or AUCinf (267 vs. 266 ng.h/mL) of eletriptan.",Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30588869/),[h·ng] / [ml],266,87120,DB01026,Ketoconazole
,26341813,AUC0-inf ratios,"The predicted AUC0-inf ratios for the interaction with ketoconazole and erythromycin were 7.7 and 1.9, respectively.",Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341813/),,7.7,87366,DB01026,Ketoconazole
,26341813,AUC0-inf ratios,"The predicted AUC0-inf ratios for the interaction with ketoconazole and erythromycin were 7.7 and 1.9, respectively.",Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341813/),,1.9,87367,DB01026,Ketoconazole
less,3972759,MICs,"The isolate of Can. albicans used, and isolates obtained after treatment with the antifungals, were susceptible to all three drugs (MICs less than or equal to 0.5 mg/l).","New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3972759/),[mg] / [l],0.5,89249,DB01026,Ketoconazole
,28535410,elimination half-life (t1/2),"In vitro studies and Phase I trials indicate that perampanel is metabolized almost exclusively by CYP3A, with an elimination half-life (t1/2) averaging approximately 105h.",Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535410/),h,105,90742,DB01026,Ketoconazole
high,28535410,AUC ratio,"Simulations further suggested that an interaction effect of ketoconazole on perampanel exposure (>2-fold) of potential clinical significance could be predicted when using larger doses of ketoconazole (e.g., 200mg every 6h) coadministered for a greater time period (e.g., 30days), with AUC ratio as high as 3.36.",Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535410/),,3.36,90743,DB01026,Ketoconazole
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB01026,Ketoconazole
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB01026,Ketoconazole
,16238904,absolute oral bioavailability,"The absolute oral bioavailability of telithromycin is approximately 57%, which is unaffected by food intake.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),%,57,91339,DB01026,Ketoconazole
,16238904,steady-state concentration,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),[μg] / [ml],2,91340,DB01026,Ketoconazole
,16238904,elimination half-life,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),h,10,91341,DB01026,Ketoconazole
,31868554,Vmax,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 ± 11.20 pmol/min/mg, 11.10 ± 1.07 μM, and 23.10 ± 1.32 μL/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),[pM] / [mg·min],256.41,92177,DB01026,Ketoconazole
,31868554,Km,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 ± 11.20 pmol/min/mg, 11.10 ± 1.07 μM, and 23.10 ± 1.32 μL/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),μM,11.10,92178,DB01026,Ketoconazole
,31868554,CLint,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 ± 11.20 pmol/min/mg, 11.10 ± 1.07 μM, and 23.10 ± 1.32 μL/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),[μl] / [mg·min],23.10,92179,DB01026,Ketoconazole
,24726088,corrected efflux ratios,"The in vitro study revealed corrected efflux ratios for teneligliptin of 6.81 and 5.27 at teneligliptin concentrations of 1 and 10 μM, respectively.",Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726088/),,6.81,93117,DB01026,Ketoconazole
,24726088,corrected efflux ratios,"The in vitro study revealed corrected efflux ratios for teneligliptin of 6.81 and 5.27 at teneligliptin concentrations of 1 and 10 μM, respectively.",Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726088/),,5.27,93118,DB01026,Ketoconazole
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],76-324,94436,DB01026,Ketoconazole
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],63-229,94437,DB01026,Ketoconazole
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],22,94438,DB01026,Ketoconazole
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],31,94439,DB01026,Ketoconazole
,20430905,clearance,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[l] / [h],22.05,94859,DB01026,Ketoconazole
,20430905,clearance,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[l] / [h],36.52,94860,DB01026,Ketoconazole
,20430905,AUC,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[mg] / [h·l],3.93,94861,DB01026,Ketoconazole
,20430905,AUC,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[mg] / [h·l],3.77,94862,DB01026,Ketoconazole
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.60,96350,DB01026,Ketoconazole
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.43,96351,DB01026,Ketoconazole
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.19,96352,DB01026,Ketoconazole
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.14,96353,DB01026,Ketoconazole
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.2,96896,DB01026,Ketoconazole
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.0,96897,DB01026,Ketoconazole
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.6,96898,DB01026,Ketoconazole
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.9,96899,DB01026,Ketoconazole
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.2,96900,DB01026,Ketoconazole
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,3.0,96901,DB01026,Ketoconazole
,20422948,constant flow rate,The elution was performed by a constant flow rate of 1.2 mL/min and the mobile phase consisted of acetonitrile and acetic acid 0.1% (85 :15 v/v).,Bioequivalence study of two formulations of 100 mg capsule of itraconazole. Quantification by tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422948/),[ml] / [min],1.2,97384,DB01026,Ketoconazole
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,431,98418,DB01026,Ketoconazole
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,435,98419,DB01026,Ketoconazole
,1357148,peak plasma concentrations,Mean peak plasma concentrations were 446 +/- 196 and 530 +/- 214 ng mL-1 at days 8 and 15.,The pharmacokinetics of oral itraconazole in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[ng] / [ml],446,99605,DB01026,Ketoconazole
,1357148,peak plasma concentrations,Mean peak plasma concentrations were 446 +/- 196 and 530 +/- 214 ng mL-1 at days 8 and 15.,The pharmacokinetics of oral itraconazole in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[ng] / [ml],530,99606,DB01026,Ketoconazole
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],2105,99607,DB01026,Ketoconazole
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],7679,99608,DB01026,Ketoconazole
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],8748,99609,DB01026,Ketoconazole
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.54,100792,DB01026,Ketoconazole
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.77,100793,DB01026,Ketoconazole
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.8,100794,DB01026,Ketoconazole
,2155951,terminal half-life,The terminal half-life of itraconazole in serum was 22.5 +/- 3.2 hours.,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),h,22.5,100795,DB01026,Ketoconazole
,2155951,penetration,"After the final dose, itraconazole penetration into cantharides-induced blister fluid was only 70%.",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,70,100796,DB01026,Ketoconazole
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.239,100797,DB01026,Ketoconazole
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.334,100798,DB01026,Ketoconazole
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.422,100799,DB01026,Ketoconazole
,21988334,Twenty-four hour,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,5.9,102209,DB01026,Ketoconazole
,21988334,Twenty-four hour,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,7.7,102210,DB01026,Ketoconazole
,21988334,urine volume,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,5.9,102211,DB01026,Ketoconazole
,21988334,urine volume,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,7.7,102212,DB01026,Ketoconazole
,21988334,Twenty-four hour urine volume,Twenty-four hour urine volume decreased from 12.3 to 8.8 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,12.3,102213,DB01026,Ketoconazole
,21988334,Twenty-four hour urine volume,Twenty-four hour urine volume decreased from 12.3 to 8.8 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,8.8,102214,DB01026,Ketoconazole
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,22.8,104479,DB01026,Ketoconazole
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,36.8,104480,DB01026,Ketoconazole
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,10.3,104481,DB01026,Ketoconazole
,20399458,maximum tolerated dose,Combination regimens using 600 mg ketoconazole daily were fairly well tolerated and the maximum tolerated dose of docetaxel was 32 mg/m(2).,A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),mg,32,104482,DB01026,Ketoconazole
,19566112,peak plasma concentrations,"Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10 mg solifenacin dose, respectively.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[ng] / [ml],24.0,106255,DB01026,Ketoconazole
,19566112,peak plasma concentrations,"Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10 mg solifenacin dose, respectively.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[ng] / [ml],40.6,106256,DB01026,Ketoconazole
,19566112,absolute bioavailability,"Studies in healthy adults have shown that the drug has high absolute bioavailability of about 90%, which does not decrease with concomitant food intake.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),%,90,106257,DB01026,Ketoconazole
,19566112,apparent volume of distribution,"Solifenacin has an apparent volume of distribution of 600 L, is 93-96% plasma protein bound, and probably crosses the blood-brain barrier.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),l,600,106258,DB01026,Ketoconazole
,19566112,total clearance,"In healthy adults, total clearance of solifenacin amounts to 7-14 L/h.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[l] / [h],7-14,106259,DB01026,Ketoconazole
,19566112,terminal elimination half-life,"The terminal elimination half-life ranges from 33 to 85 hours, permitting once-daily administration.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),h,33 to 85,106260,DB01026,Ketoconazole
,19566112,renal clearance,"Urinary excretion plays a minor role in the elimination of solifenacin, resulting in renal clearance of 0.67-1.51 L/h.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[l] / [h],0.67-1.51,106261,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],482,108437,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],206,108438,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],167,108439,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],<,108440,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],100,108441,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],3160,108442,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],2430,108443,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],937,108444,DB01026,Ketoconazole
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],534,108445,DB01026,Ketoconazole
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],1660,108446,DB01026,Ketoconazole
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],7715 to 15319,108447,DB01026,Ketoconazole
,9408807,maximum QTc,"On the final day of coadministration, the rate-corrected QT interval (QTc) was unaltered compared with terfenadine dosed alone; maximum QTc values (mean [SEM]) were 404 (4) and 405 (5) msec, respectively.",Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),ms,404,108506,DB01026,Ketoconazole
,9408807,maximum QTc,"On the final day of coadministration, the rate-corrected QT interval (QTc) was unaltered compared with terfenadine dosed alone; maximum QTc values (mean [SEM]) were 404 (4) and 405 (5) msec, respectively.",Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),ms,405,108507,DB01026,Ketoconazole
,9408807,steady-state area under the curve (AUC)tau,Terfenadine pharmacokinetics were also unchanged; geometric mean steady-state area under the curve (AUC)tau values were 30.0 ng.hr/mL during coadministration compared with 30.8 ng.hr/mL when dosed alone (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[h·ng] / [ml],30.0,108508,DB01026,Ketoconazole
,9408807,steady-state area under the curve (AUC)tau,Terfenadine pharmacokinetics were also unchanged; geometric mean steady-state area under the curve (AUC)tau values were 30.0 ng.hr/mL during coadministration compared with 30.8 ng.hr/mL when dosed alone (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[h·ng] / [ml],30.8,108509,DB01026,Ketoconazole
,9408807,Cmax,The corresponding Cmax values were 3.68 and 3.64 ng/mL (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[ng] / [ml],3.68,108510,DB01026,Ketoconazole
,9408807,Cmax,The corresponding Cmax values were 3.68 and 3.64 ng/mL (p > 0.05).,Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408807/),[ng] / [ml],3.64,108511,DB01026,Ketoconazole
,6289740,mean plasma concentrations,"The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μg] / [ml],1.7,109925,DB01026,Ketoconazole
,6289740,mean plasma concentrations,"The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μg] / [ml],0.9,109926,DB01026,Ketoconazole
,6289740,mean plasma concentrations,"The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μg] / [ml],0.7,109927,DB01026,Ketoconazole
,6289740,Half-lives,Half-lives ranged from 1.3 to 11.6 h in individual patients.,Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),h,1.3 to 11.6,109928,DB01026,Ketoconazole
,6289740,half-life,The mean half-life for all patients studied was 3.7 +/- 0.6 h on day 1.,Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),h,3.7,109929,DB01026,Ketoconazole
,6289740,area under the curve,"The calculated area under the curve was 12.0 +/- 4.7 micrograms-h/ml on day 1; it increased after 7 and 14 days of administration (every-6-h schedule), suggesting plasma binding or wide drug distribution or both.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μgrams-h] / [ml],12.0,109930,DB01026,Ketoconazole
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,107.7,111419,DB01026,Ketoconazole
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,212,111420,DB01026,Ketoconazole
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,12.2,111421,DB01026,Ketoconazole
,2544431,relative systemic availability,The relative systemic availability of itraconazole capsules compared with solution averaged 39.8% in the fasting state but 102% in the post-prandial state.,The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544431/),%,39.8,113041,DB01026,Ketoconazole
,2544431,relative systemic availability,The relative systemic availability of itraconazole capsules compared with solution averaged 39.8% in the fasting state but 102% in the post-prandial state.,The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544431/),%,102,113042,DB01026,Ketoconazole
,10972485,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[μg] / [ml],2.3,113127,DB01026,Ketoconazole
,10972485,time to Cmax (tmax),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,2.3,113128,DB01026,Ketoconazole
,10972485,bioavailability (F),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,65.5,113129,DB01026,Ketoconazole
,10972485,AUCs,The AUCs of BG and 8-oxo-BG were 13.1 +/- 4.6 microg x h/ml and 1.7 +/- 0.4 microg x h/ml after oral administration of BG.,Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[h·μg] / [ml],13.1,113130,DB01026,Ketoconazole
,10972485,AUCs,The AUCs of BG and 8-oxo-BG were 13.1 +/- 4.6 microg x h/ml and 1.7 +/- 0.4 microg x h/ml after oral administration of BG.,Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[h·μg] / [ml],1.7,113131,DB01026,Ketoconazole
,10972485,mean absorption time,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,2.0,113132,DB01026,Ketoconazole
,10972485,mean absorption time,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,6.0,113133,DB01026,Ketoconazole
,10972485,tmax,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,5,113134,DB01026,Ketoconazole
,10972485,Cmax,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[μg] / [ml],0.96,113135,DB01026,Ketoconazole
,10972485,AUC0-inf ratio,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),,0.12,113136,DB01026,Ketoconazole
,10972485,AUC0-inf ratio,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),,0.04,113137,DB01026,Ketoconazole
,10972485,bioavailability,"The bioavailability of BG was not changed (65.5% vs 56.9%, P= 0.78).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,65.5,113138,DB01026,Ketoconazole
,10972485,bioavailability,"The bioavailability of BG was not changed (65.5% vs 56.9%, P= 0.78).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,56.9,113139,DB01026,Ketoconazole
=,15304429,AUCi/AUC,"Although there are reported examples of clinically relevant drug-drug interactions for UGT substrates, exposure increases of the aglycone are rarely greater than 100% in the presence of an inhibitor relative to its absence (i.e., AUCi/AUC < or = 2).",Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304429/),,2,113760,DB01026,Ketoconazole
,2781141,systemic clearance,Ketoconazole decreased the systemic clearance of cyclosporine from 7.0 ml/min/kg to 2.5 ml/min/kg.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),[ml] / [kg·min],7.0,114731,DB01026,Ketoconazole
,2781141,systemic clearance,Ketoconazole decreased the systemic clearance of cyclosporine from 7.0 ml/min/kg to 2.5 ml/min/kg.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),[ml] / [kg·min],2.5,114732,DB01026,Ketoconazole
,2781141,terminal disposition rate constant,The terminal disposition rate constant was also decreased significantly from 0.0794 to 0.0354 hrs-1.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),1/[h],0.0794,114733,DB01026,Ketoconazole
,2781141,terminal disposition rate constant,The terminal disposition rate constant was also decreased significantly from 0.0794 to 0.0354 hrs-1.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),1/[h],0.0354,114734,DB01026,Ketoconazole
≥,28185218,trough level,"Furthermore, a strong relationship between pazopanib trough level ≥20 mg/L and both tumor shrinkage and progression-free survival has been established.",Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185218/),[mg] / [l],20,115836,DB01026,Ketoconazole
,21395644,t(max),Median t(max) was 6.0 h with both regimens.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),h,6.0,116760,DB01026,Ketoconazole
,21395644,apparent oral clearance,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),1/[lh],346,116761,DB01026,Ketoconazole
,21395644,apparent oral clearance,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),1/[lh],87.1,116762,DB01026,Ketoconazole
,21395644,elimination half-life,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),h,11.7,116763,DB01026,Ketoconazole
,21395644,elimination half-life,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),h,18.0,116764,DB01026,Ketoconazole
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.24,124543,DB01026,Ketoconazole
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,12.54,124544,DB01026,Ketoconazole
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,0.81,124545,DB01026,Ketoconazole
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,1.49,124546,DB01026,Ketoconazole
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,3.90,124547,DB01026,Ketoconazole
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.35,124548,DB01026,Ketoconazole
,15248189,full-run time,"Plasma harvested was analysed for ketoconazole by a modified and validated HPLC method with UV detection in the range 400-14000 ng/ml, using 200 microl of plasma in a full-run time of 2.5 min.",Bioequivalence evaluation of two brands of ketoconazole tablets (Onofin-K and Nizoral) in a healthy female Mexican population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248189/),min,2.5,125452,DB01026,Ketoconazole
,10086837,half-life,Serum KCZ concentrations showed an apparent nonlinear pattern of decline with a short half-life (1.38 h).,Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086837/),h,1.38,127287,DB01026,Ketoconazole
,17630547,area under the curve (AUC),"The mean saquinavir area under the curve (AUC) during boosting with ritonavir was 57.93 +/- 27.96 mg/h/l, maximum observed concentration (Cmax) was 7.50 +/- 3.45 mg/l and concentration at 24 h (Cmin) was 0.35 +/- 0.30 mg/l.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [h·l],57.93,127544,DB01026,Ketoconazole
,17630547,maximum observed concentration (Cmax),"The mean saquinavir area under the curve (AUC) during boosting with ritonavir was 57.93 +/- 27.96 mg/h/l, maximum observed concentration (Cmax) was 7.50 +/- 3.45 mg/l and concentration at 24 h (Cmin) was 0.35 +/- 0.30 mg/l.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],7.50,127545,DB01026,Ketoconazole
,17630547,concentration at 24 h (Cmin),"The mean saquinavir area under the curve (AUC) during boosting with ritonavir was 57.93 +/- 27.96 mg/h/l, maximum observed concentration (Cmax) was 7.50 +/- 3.45 mg/l and concentration at 24 h (Cmin) was 0.35 +/- 0.30 mg/l.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],0.35,127546,DB01026,Ketoconazole
,17630547,AUC,"When ketoconazole was used, the saquinavir AUC, Cmax, and Cmin were 12.00 +/- 6.97 mg/h/l, 2.43 +/- 1.35 mg/l and 0.03 +/- 0.04 mg/l, respectively.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [h·l],12.00,127547,DB01026,Ketoconazole
,17630547,Cmax,"When ketoconazole was used, the saquinavir AUC, Cmax, and Cmin were 12.00 +/- 6.97 mg/h/l, 2.43 +/- 1.35 mg/l and 0.03 +/- 0.04 mg/l, respectively.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],2.43,127548,DB01026,Ketoconazole
,17630547,Cmin,"When ketoconazole was used, the saquinavir AUC, Cmax, and Cmin were 12.00 +/- 6.97 mg/h/l, 2.43 +/- 1.35 mg/l and 0.03 +/- 0.04 mg/l, respectively.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],0.03,127549,DB01026,Ketoconazole
,17630547,trough concentrations,"Although saquinavir AUC might still be adequate for treatment, concentrations at 24 h reached levels below the recommended trough concentrations of 0.1 mg/l, which may result in selection of resistant HIV-1 viral strains.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],0.1,127550,DB01026,Ketoconazole
,16997909,Cmax,"Cmax increased from 23 ng/ml (95% CI 19-29 ng/ml) to 55 ng/ml (95% CI 46-66 ng/ml), p < 0.0001.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[ng] / [ml],23,127959,DB01026,Ketoconazole
,16997909,Cmax,"Cmax increased from 23 ng/ml (95% CI 19-29 ng/ml) to 55 ng/ml (95% CI 46-66 ng/ml), p < 0.0001.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[ng] / [ml],55,127960,DB01026,Ketoconazole
,16997909,AUCs,"AUCs [median (range)] were 0.20 mg . min/ml (0.05-0.81 mg . min/ml) and 1.94 mg . min/ml (0.25-25.4 mg . min/ml) at baseline and inhibition phase, with CV% of 41 and 61%, respectively.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[mg·min] / [ml],0.20,127961,DB01026,Ketoconazole
,16997909,AUCs,"AUCs [median (range)] were 0.20 mg . min/ml (0.05-0.81 mg . min/ml) and 1.94 mg . min/ml (0.25-25.4 mg . min/ml) at baseline and inhibition phase, with CV% of 41 and 61%, respectively.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[mg·min] / [ml],1.94,127962,DB01026,Ketoconazole
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.34,128355,DB01026,Ketoconazole
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.06,128356,DB01026,Ketoconazole
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.21,128357,DB01026,Ketoconazole
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,5.8,128358,DB01026,Ketoconazole
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,7.6,128359,DB01026,Ketoconazole
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,6.7,128360,DB01026,Ketoconazole
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,3.23,129349,DB01026,Ketoconazole
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129350,DB01026,Ketoconazole
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,2.26,129351,DB01026,Ketoconazole
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129352,DB01026,Ketoconazole
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.52,129353,DB01026,Ketoconazole
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.343,129709,DB01026,Ketoconazole
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.343,129710,DB01026,Ketoconazole
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.269,129711,DB01026,Ketoconazole
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.267,129712,DB01026,Ketoconazole
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.534,129713,DB01026,Ketoconazole
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.531,129714,DB01026,Ketoconazole
,12496753,bioavailability,"As expected, ketoconazole markedly increased the mean bioavailability to 0.838 (2.4-fold), the mean ER(H) was decreased 3.7-fold, and the mean ER(G) was decreased 5.7-fold.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.838,129715,DB01026,Ketoconazole
,22884766,C(max),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[ng] / [ml],58.4,130017,DB01026,Ketoconazole
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],2980,130018,DB01026,Ketoconazole
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],"23,000",130019,DB01026,Ketoconazole
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],876,130020,DB01026,Ketoconazole
,22884766,AUC(0-24),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],876,130021,DB01026,Ketoconazole
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],7080,130022,DB01026,Ketoconazole
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],2740,130023,DB01026,Ketoconazole
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],"22,200",130024,DB01026,Ketoconazole
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.40,132812,DB01026,Ketoconazole
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.40,132813,DB01026,Ketoconazole
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.33,132814,DB01026,Ketoconazole
,18448569,AUC increase ratios,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1.7,132815,DB01026,Ketoconazole
,18448569,AUC increase ratios,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1.5,132816,DB01026,Ketoconazole
,18448569,f(m CYP2D6),"Moreover, the f(m CYP2D6) of R-125528 estimated to be almost 1 would well explain the accumulation of R-125528 observed with the quinidine treatment.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1,132817,DB01026,Ketoconazole
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],213,134769,DB01026,Ketoconazole
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],467,134770,DB01026,Ketoconazole
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],375,134771,DB01026,Ketoconazole
,17922078,Km,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),μM,12.3,134955,DB01026,Ketoconazole
,17922078,Vmax,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),[nM] / [mg·min],2.01,134956,DB01026,Ketoconazole
,12580990,Peff,"Peff of fexofenadine was low according to the BCS (0.11 +/- 0.11 and 0.04 +/- 0.13 x 10(-4) cm s(-1) in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference -0.37, 0.51).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.11,135222,DB01026,Ketoconazole
,12580990,Peff,"Peff of fexofenadine was low according to the BCS (0.11 +/- 0.11 and 0.04 +/- 0.13 x 10(-4) cm s(-1) in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference -0.37, 0.51).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.04,135223,DB01026,Ketoconazole
,12580990,Peff,"After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0.29 +/- 0.47 and 0.22 +/- 0.31 x 10-4 cm s(-1) in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference -0.62, 0.27 for T1 0-100 min vs T2 0-100 min; -0.54, 0.34 for T1 0-100 min vs T2 100-200 min).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.29,135224,DB01026,Ketoconazole
,12580990,Peff,"After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0.29 +/- 0.47 and 0.22 +/- 0.31 x 10-4 cm s(-1) in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference -0.62, 0.27 for T1 0-100 min vs T2 0-100 min; -0.54, 0.34 for T1 0-100 min vs T2 100-200 min).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.22,135225,DB01026,Ketoconazole
,12580990,plasma AUC,"Fexofenadine plasma AUC from 0-100 mg showed no significant difference after pretreatment with ketoconazole (55 +/- 101 and 51 +/- 33 micro g ml(-1) min(-1) respectively; 95% CI on the difference -108, 115).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[μg] / [min·ml],55,135226,DB01026,Ketoconazole
,12580990,plasma AUC,"Fexofenadine plasma AUC from 0-100 mg showed no significant difference after pretreatment with ketoconazole (55 +/- 101 and 51 +/- 33 micro g ml(-1) min(-1) respectively; 95% CI on the difference -108, 115).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[μg] / [min·ml],51,135227,DB01026,Ketoconazole
,12580990,Total plasma AUC (0-720 min),"Total plasma AUC (0-720 min) was 318 +/- 426 and 426 +/- 232 ng ml(-1) min in T1 and T2, respectively (95% CI on the difference -622, 405).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[min·ng] / [ml],318,135228,DB01026,Ketoconazole
,12580990,Total plasma AUC (0-720 min),"Total plasma AUC (0-720 min) was 318 +/- 426 and 426 +/- 232 ng ml(-1) min in T1 and T2, respectively (95% CI on the difference -622, 405).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[min·ng] / [ml],426,135229,DB01026,Ketoconazole
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,10.5,135601,DB01026,Ketoconazole
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,0.07,135602,DB01026,Ketoconazole
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,31.1,135603,DB01026,Ketoconazole
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136808,DB01026,Ketoconazole
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136809,DB01026,Ketoconazole
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136810,DB01026,Ketoconazole
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136811,DB01026,Ketoconazole
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136812,DB01026,Ketoconazole
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136813,DB01026,Ketoconazole
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],312,136814,DB01026,Ketoconazole
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136815,DB01026,Ketoconazole
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],3536,136816,DB01026,Ketoconazole
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,9.4,136817,DB01026,Ketoconazole
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,12.4,136818,DB01026,Ketoconazole
,29117990,area under the curve ratio,The simulated midazolam area under the curve ratio of 0.54 and an accompanying observed 1.9-fold increase in the CYP3A4 activity of biomarker 4β-hydroxycholesterol indicated a weak-to-moderate CYP3A4 induction by midostaurin and its metabolites at steady state in patients with advSM.,Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117990/),,0.54,137187,DB01026,Ketoconazole
,16019953,extraction ratio,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,93,137207,DB01026,Ketoconazole
,16019953,extraction ratio,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,77,137208,DB01026,Ketoconazole
,16019953,bioavailability,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,23,137209,DB01026,Ketoconazole
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137989,DB01026,Ketoconazole
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137990,DB01026,Ketoconazole
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137991,DB01026,Ketoconazole
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137992,DB01026,Ketoconazole
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137993,DB01026,Ketoconazole
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137994,DB01026,Ketoconazole
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,17.8,138323,DB01026,Ketoconazole
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,14.6,138324,DB01026,Ketoconazole
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,2.25,138325,DB01026,Ketoconazole
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,31.4,138326,DB01026,Ketoconazole
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,17.1,138327,DB01026,Ketoconazole
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,1.70,138328,DB01026,Ketoconazole
,3767339,maximum concentrations,"The absorption of ketoconazole was rapid, with mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 micrograms/ml attained at 1.7, 1.2, and 1.0 h, respectively, after administration of the tablet, suspension, and solution, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[μg] / [ml],4.2,138651,DB01026,Ketoconazole
,3767339,maximum concentrations,"The absorption of ketoconazole was rapid, with mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 micrograms/ml attained at 1.7, 1.2, and 1.0 h, respectively, after administration of the tablet, suspension, and solution, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[μg] / [ml],5.0,138652,DB01026,Ketoconazole
,3767339,maximum concentrations,"The absorption of ketoconazole was rapid, with mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 micrograms/ml attained at 1.7, 1.2, and 1.0 h, respectively, after administration of the tablet, suspension, and solution, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[μg] / [ml],6.2,138653,DB01026,Ketoconazole
,3767339,distribution,"The mean distribution and elimination half-life values were 1.5 to 1.7 and 7.5 to 7.9 h, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),h,1.5 to 1.7,138654,DB01026,Ketoconazole
,3767339,elimination half-life,"The mean distribution and elimination half-life values were 1.5 to 1.7 and 7.5 to 7.9 h, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),h,7.5 to 7.9,138655,DB01026,Ketoconazole
,3767339,oral clearance of the solution dose,"The mean oral clearance of the solution dose was 209 (+/- 82.9 [standard deviation]) ml/min, and the mean apparent volume of distribution was 88.31 (+/- 68.72) liters.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],209,138656,DB01026,Ketoconazole
,3767339,apparent volume of distribution,"The mean oral clearance of the solution dose was 209 (+/- 82.9 [standard deviation]) ml/min, and the mean apparent volume of distribution was 88.31 (+/- 68.72) liters.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),l,88.31,138657,DB01026,Ketoconazole
,3767339,relative bioavailabilities,"The relative bioavailabilities for the tablet and suspension were 81.2 (+/- 33.5) and 89.0 (+/- 23.1)%, respectively, of that of the solution.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),%,81.2,138658,DB01026,Ketoconazole
,3767339,relative bioavailabilities,"The relative bioavailabilities for the tablet and suspension were 81.2 (+/- 33.5) and 89.0 (+/- 23.1)%, respectively, of that of the solution.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),%,89.0,138659,DB01026,Ketoconazole
,3767339,oral clearance,"The mean oral clearance decreased from 244.9 to 123.6 and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 mg.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],244.9,138660,DB01026,Ketoconazole
,3767339,oral clearance,"The mean oral clearance decreased from 244.9 to 123.6 and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 mg.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],123.6,138661,DB01026,Ketoconazole
,3767339,oral clearance,"The mean oral clearance decreased from 244.9 to 123.6 and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 mg.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],80.0,138662,DB01026,Ketoconazole
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2827,139737,DB01026,Ketoconazole
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2072,139738,DB01026,Ketoconazole
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],247,139739,DB01026,Ketoconazole
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],236,139740,DB01026,Ketoconazole
,24962564,"AUC(0,∞)","Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],869,139741,DB01026,Ketoconazole
,24962564,Cmax,"Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),,290,139742,DB01026,Ketoconazole
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2980,139743,DB01026,Ketoconazole
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],3120,139744,DB01026,Ketoconazole
,20108303,corrected QT (QTc),"Coadministration of ketoconazole led to a marked increase in dasatinib exposure, which was correlated with an increase in corrected QT (QTc) values of approximately 6 msec.",Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108303/),,6,140551,DB01026,Ketoconazole
,21317368,bioavailability,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.36,140582,DB01026,Ketoconazole
,21317368,bioavailability,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.91,140583,DB01026,Ketoconazole
,21317368,terminal half-life,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),h,1.6,140584,DB01026,Ketoconazole
,21317368,terminal half-life,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),h,4.0,140585,DB01026,Ketoconazole
∼,21317368,f(a) · F(G),"From deconvolution, it was found that the absorption rate from the intestine to the portal vein was rapid, and the product of the fraction absorbed and the fraction that escaped gut wall metabolism was high (f(a) · F(G) ∼ 1).","In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,1,140586,DB01026,Ketoconazole
,21317368,liver extraction ratio,"After intrajejunal administration, from 1 to 6 h, the liver extraction ratio was significantly (p < 0.05) reduced by ketoconazole treatment from intermediate (0.41 ± 0.21) to low (0.21 ± 0.10).","In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.41,140587,DB01026,Ketoconazole
,21317368,liver extraction ratio,"After intrajejunal administration, from 1 to 6 h, the liver extraction ratio was significantly (p < 0.05) reduced by ketoconazole treatment from intermediate (0.41 ± 0.21) to low (0.21 ± 0.10).","In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.21,140588,DB01026,Ketoconazole
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1·mg·nM] / [h],0.06,140625,DB01026,Ketoconazole
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.08-0.28,140626,DB01026,Ketoconazole
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.75,140627,DB01026,Ketoconazole
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,5,140628,DB01026,Ketoconazole
,30198595,minimum plasma concentration,"However, all scenarios suggest that a dose of 62.5 mg weekly achieves or exceeds the exposure in adults following a 250 mg weekly dose and results in a minimum plasma concentration of 620 ng ml-1 , which is considered necessary to achieve 95% prophylactic efficacy.",Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198595/),[ng] / [ml],620,140651,DB01026,Ketoconazole
,9210686,maximum concentration in plasma (Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[ng] / [ml],511,141082,DB01026,Ketoconazole
,9210686,maximum concentration in plasma (Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[ng] / [ml],525,141083,DB01026,Ketoconazole
,9210686,time at which,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,3.0,141084,DB01026,Ketoconazole
,9210686,Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,3.0,141085,DB01026,Ketoconazole
,9210686,Cmax,No statistically significant (P > 0.05) differences were seen in RBT absorption parameter estimates between days 13 and 16: maximum concentration in plasma (Cmax; 511 +/- 341 ng/ml versus 525 +/- 254 ng/ml) and the time at which Cmax was observed (3.0 versus 2.5 h).,Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),h,2.5,141086,DB01026,Ketoconazole
,9210686,area under the concentration-time curve from 0 to 24 h (AUC(0-tau)),"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[h·ng] / [ml],"5,650",141087,DB01026,Ketoconazole
,9210686,area under the concentration-time curve from 0 to 24 h (AUC(0-tau)),"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[h·ng] / [ml],"5,023",141088,DB01026,Ketoconazole
,9210686,oral clearance,"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[l] / [h·kg],1.28,141089,DB01026,Ketoconazole
,9210686,oral clearance,"The mean RBT estimates for area under the concentration-time curve from 0 to 24 h (AUC(0-tau)) (5,650 versus 5,023 ng x h/ml) and for oral clearance (1.28 versus 1.18 liter/h/kg) on both study days were also similar.",Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210686/),[l] / [h·kg],1.18,141090,DB01026,Ketoconazole
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],110,141167,DB01026,Ketoconazole
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],272,141168,DB01026,Ketoconazole
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],553,141169,DB01026,Ketoconazole
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],412,141170,DB01026,Ketoconazole
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],"1,070",141171,DB01026,Ketoconazole
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],"1,980",141172,DB01026,Ketoconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,15,141173,DB01026,Ketoconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,34,141174,DB01026,Ketoconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,20.7,141175,DB01026,Ketoconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,36.5,141176,DB01026,Ketoconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,25,141177,DB01026,Ketoconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,41.7,141178,DB01026,Ketoconazole
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"1,320",141179,DB01026,Ketoconazole
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"4,160",141180,DB01026,Ketoconazole
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"12,600",141181,DB01026,Ketoconazole
,25165011,Extraction recovery,Extraction recovery of GDC-0980 was between 72.4% and 75.5%.,"A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),%,72.4,141898,DB01026,Ketoconazole
,25165011,Extraction recovery,Extraction recovery of GDC-0980 was between 72.4% and 75.5%.,"A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),%,75.5,141899,DB01026,Ketoconazole
,25165011,Cmax,"Mean pharmacokinetic parameters determined using this method for the day 1 control group in a phase I trial were: Cmax=11.1ng/mL, AUC0-inf=108ngh/mL, and T1/2=13.1h.","A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),[ng] / [ml],11.1,141900,DB01026,Ketoconazole
,25165011,AUC0-inf,"Mean pharmacokinetic parameters determined using this method for the day 1 control group in a phase I trial were: Cmax=11.1ng/mL, AUC0-inf=108ngh/mL, and T1/2=13.1h.","A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),[ngh] / [ml],108,141901,DB01026,Ketoconazole
,25165011,T1/2,"Mean pharmacokinetic parameters determined using this method for the day 1 control group in a phase I trial were: Cmax=11.1ng/mL, AUC0-inf=108ngh/mL, and T1/2=13.1h.","A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),h,13.1,141902,DB01026,Ketoconazole
,29851709,half-life,"Post-treatment washout of posaconazole was slow in normals (mean half-life 31 hours), and further prolonged in obese subjects (53 hours).","Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29851709/),h,31,143357,DB01026,Ketoconazole
,29851709,half-life,"Post-treatment washout of posaconazole was slow in normals (mean half-life 31 hours), and further prolonged in obese subjects (53 hours).","Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29851709/),h,53,143358,DB01026,Ketoconazole
,23677771,effective plasma half-life,"Axitinib has a short effective plasma half-life (range 2.5-6.1 h), and the plasma accumulation of axitinib is in agreement with what is expected based on the plasma half-life of the drug.",Clinical pharmacology of axitinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),h,2.5-6.1,143799,DB01026,Ketoconazole
,23677771,absolute bioavailability,The mean absolute bioavailability of axitinib is 58 %.,Clinical pharmacology of axitinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),%,58,143800,DB01026,Ketoconazole
,23677771,C max,"In patients with advanced renal cell carcinoma, at the 5-mg twice-daily dose in the fed state, the geometric mean (% coefficient of variation) C max and area under the plasma concentration-time curve (AUC) from time 0-24 h (AUC24) were 27.8 ng/mL (79 %) and 265 ng·h/mL (77 %), respectively.",Clinical pharmacology of axitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),[ng] / [ml],27.8,143801,DB01026,Ketoconazole
,23677771,area under the plasma concentration-time curve (AUC) from time 0-24 h (AUC24),"In patients with advanced renal cell carcinoma, at the 5-mg twice-daily dose in the fed state, the geometric mean (% coefficient of variation) C max and area under the plasma concentration-time curve (AUC) from time 0-24 h (AUC24) were 27.8 ng/mL (79 %) and 265 ng·h/mL (77 %), respectively.",Clinical pharmacology of axitinib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),[h·ng] / [ml],265,143802,DB01026,Ketoconazole
<,17851638,solubility,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),[μg] / [ml],0.1,146683,DB01026,Ketoconazole
<,17851638,log Pe,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),,5.0,146684,DB01026,Ketoconazole
>,17851638,plasma protein binding,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),%,70,146685,DB01026,Ketoconazole
,15039292,clearance,"Using an alternative method, based on normalization of in vitro human data with the ratio of in vivo to in vitro animal data, the in vivo clearance in humans was predicted to be 0.39 l/h/kg.","Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039292/),[l] / [h·kg],0.39,147080,DB01026,Ketoconazole
,11243504,half-life,"Desloratadine has a half-life of 21-24 h, permitting once-daily dosing.",The pharmacologic profile of desloratadine: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243504/),h,21-24,148009,DB01026,Ketoconazole
,8227460,maximum peak plasma concentration (Cmax),"The average DDI maximum peak plasma concentration (Cmax) value at steady state was significantly less when DDI was administered with KET (1836 ng/mL) than when DDI was administered alone (2094 ng/mL), although the magnitude of the decrease was only 12%.",Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[ng] / [ml],1836,150299,DB01026,Ketoconazole
,8227460,maximum peak plasma concentration (Cmax),"The average DDI maximum peak plasma concentration (Cmax) value at steady state was significantly less when DDI was administered with KET (1836 ng/mL) than when DDI was administered alone (2094 ng/mL), although the magnitude of the decrease was only 12%.",Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[ng] / [ml],2094,150300,DB01026,Ketoconazole
,8227460,area under the curve (AUC(0-tau)),Didanosine area under the curve (AUC(0-tau)) for the combination (2872 hr.ng/mL) was 8% less than when DDI was given alone (3107 hr.ng/mL); the difference was not significant.,Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[h·ng] / [ml],2872,150301,DB01026,Ketoconazole
,8227460,area under the curve (AUC(0-tau)),Didanosine area under the curve (AUC(0-tau)) for the combination (2872 hr.ng/mL) was 8% less than when DDI was given alone (3107 hr.ng/mL); the difference was not significant.,Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[h·ng] / [ml],3107,150302,DB01026,Ketoconazole
,10579473,Total bioavailability,Total bioavailability increased from 25% to 80% (P < .001).,Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579473/),%,25,150793,DB01026,Ketoconazole
,10579473,Total bioavailability,Total bioavailability increased from 25% to 80% (P < .001).,Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579473/),%,80,150794,DB01026,Ketoconazole
,8464816,volume of distribution,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[l] / [kg],3,150827,DB01026,Ketoconazole
,8464816,volume of distribution,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[l] / [kg],less,150828,DB01026,Ketoconazole
,8464816,volume of distribution,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[l] / [kg],1,150829,DB01026,Ketoconazole
,8464816,plasma clearance,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[ml] / [kg·min],25,150830,DB01026,Ketoconazole
,8464816,Vmax,A Vmax of 3.2 mg/hr/kg and Km of 2.1 mg/L were obtained by nonlinear regression analysis.,Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[mg] / [h·kg],3.2,150831,DB01026,Ketoconazole
,8464816,Km,A Vmax of 3.2 mg/hr/kg and Km of 2.1 mg/L were obtained by nonlinear regression analysis.,Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[mg] / [l],2.1,150832,DB01026,Ketoconazole
,8464816,kidney:plasma partition coefficient,"In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),,1.8,150833,DB01026,Ketoconazole
,8464816,blood:plasma concentration ratio,"In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),,0.6,150834,DB01026,Ketoconazole
,8464816,plasma binding,"In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),%,96,150835,DB01026,Ketoconazole
,31051051,CL,"Typical midazolam CL and F estimates were 32.9 L/h and 0.31 for the constituent state, while the ratio of inducer/inhibitor for midazolam CL and CL/F for the induced/inhibited (rifampin/ketoconazole) states were 14.2 and 85.3.","Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051051/),[l] / [h],32.9,152473,DB01026,Ketoconazole
,31051051,F,"Typical midazolam CL and F estimates were 32.9 L/h and 0.31 for the constituent state, while the ratio of inducer/inhibitor for midazolam CL and CL/F for the induced/inhibited (rifampin/ketoconazole) states were 14.2 and 85.3.","Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051051/),,0.31,152474,DB01026,Ketoconazole
,32814084,particle,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),nm,210.9,152498,DB01026,Ketoconazole
,32814084,particle,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),nm,167.8,152499,DB01026,Ketoconazole
,32814084,entrapment efficiency,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),%,84.8,152500,DB01026,Ketoconazole
,32814084,entrapment efficiency,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),%,95.3,152501,DB01026,Ketoconazole
,20156150,elimination half-life,The elimination half-life of galantamine is about 7-8 hours.,"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20156150/),h,7-8,155466,DB01026,Ketoconazole
,20156150,protein binding,Galantamine has low protein binding (28.3-33.8%) and has an apparent steady-state volume of distribution (V(ss)) of 193 L.,"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20156150/),%,28.3-33.8,155467,DB01026,Ketoconazole
,20156150,apparent steady-state volume of distribution (V(ss)),Galantamine has low protein binding (28.3-33.8%) and has an apparent steady-state volume of distribution (V(ss)) of 193 L.,"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20156150/),l,193,155468,DB01026,Ketoconazole
,17234419,IC50,"The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor.",Azetidinones as vasopressin V1a antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17234419/),nM,45,156010,DB01026,Ketoconazole
<,17234419,Ki,"Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with Ki values <1nM and brain levels after oral dosing approximately 100-fold higher than receptor affinities.",Azetidinones as vasopressin V1a antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17234419/),nM,1,156011,DB01026,Ketoconazole
,14616424,clearance (CL),"The values (mean +/- standard error of the mean) for clearance (CL) and volume of distribution of the central compartment were 40.2 +/- 2.0 l h-1 and 34.7 +/- 4.6 l h-1, respectively, in a typical male CYP2D6 homozygote-extensive metabolizer (Hom-EM).","Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616424/),[l] / [h],40.2,156976,DB01026,Ketoconazole
,14616424,volume of distribution of the central compartment,"The values (mean +/- standard error of the mean) for clearance (CL) and volume of distribution of the central compartment were 40.2 +/- 2.0 l h-1 and 34.7 +/- 4.6 l h-1, respectively, in a typical male CYP2D6 homozygote-extensive metabolizer (Hom-EM).","Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616424/),[l] / [h],34.7,156977,DB01026,Ketoconazole
,14616424,absolute bioavailability (F),"The absolute bioavailability (F) of darifenacin in a Hom-EM after doses of 7.5, 15 or 30 mg extended release formulation (CR) was 15, 19 and 25%, respectively.","Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616424/),%,15,156978,DB01026,Ketoconazole
,14616424,absolute bioavailability (F),"The absolute bioavailability (F) of darifenacin in a Hom-EM after doses of 7.5, 15 or 30 mg extended release formulation (CR) was 15, 19 and 25%, respectively.","Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616424/),%,19,156979,DB01026,Ketoconazole
,14616424,absolute bioavailability (F),"The absolute bioavailability (F) of darifenacin in a Hom-EM after doses of 7.5, 15 or 30 mg extended release formulation (CR) was 15, 19 and 25%, respectively.","Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616424/),%,25,156980,DB01026,Ketoconazole
,11192474,half-life,"The plasma concentration-time profile following oral administration is best described by a 1-compartment model, and the mean half-life (approximately 12 hours) is consistent with the recommendation to administer the drug twice daily.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),h,12,158838,DB01026,Ketoconazole
,11192474,absolute bioavailability,"The absolute bioavailability is 94.5%, and maximal concentrations are generally achieved within 2 to 4 hours.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),%,94.5,158839,DB01026,Ketoconazole
,9536021,IC50,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.85,162462,DB01026,Ketoconazole
,9536021,Ki,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.50,162463,DB01026,Ketoconazole
,9536021,IC50,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.56,162464,DB01026,Ketoconazole
,9536021,Ki,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.17,162465,DB01026,Ketoconazole
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1.11,162466,DB01026,Ketoconazole
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1. 58,162467,DB01026,Ketoconazole
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,5.73,162468,DB01026,Ketoconazole
,11782899,maximum concentration (C(max)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],0.60 to 1.6,162836,DB01026,Ketoconazole
,11782899,area under the concentration versus time curve (AUC(0-infinity)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],8,162837,DB01026,Ketoconazole
,11782899,area under the concentration versus time curve (AUC(0-infinity)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],24,162838,DB01026,Ketoconazole
,11782899,time to reach C(max) (t(max)),The median time to reach C(max) (t(max)) was increased from 2 to 6 h.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,2,162839,DB01026,Ketoconazole
,11782899,time to reach C(max) (t(max)),The median time to reach C(max) (t(max)) was increased from 2 to 6 h.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,6,162840,DB01026,Ketoconazole
,11782899,Terminal half-life,Terminal half-life (10 h) and mean residence time (MRT; 15 h) were unaffected.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10,162841,DB01026,Ketoconazole
,11782899,mean residence time (MRT,Terminal half-life (10 h) and mean residence time (MRT; 15 h) were unaffected.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,15,162842,DB01026,Ketoconazole
,11782899,C(max),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],1.3,162843,DB01026,Ketoconazole
,11782899,C(max),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],2,162844,DB01026,Ketoconazole
,11782899,AUC(0-infinity),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],28,162845,DB01026,Ketoconazole
,11782899,t(max),The t(max) was unchanged (3 h).,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,3,162846,DB01026,Ketoconazole
,11782899,Terminal half-life,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,15.4,162847,DB01026,Ketoconazole
,11782899,Terminal half-life,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10.7,162848,DB01026,Ketoconazole
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10.7,162849,DB01026,Ketoconazole
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,19.9,162850,DB01026,Ketoconazole
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,16.0,162851,DB01026,Ketoconazole
,16791583,log10,The mean log10(omeprazole/omeprazole sulfone) ratio was 0.18 3 h after intake of omeprazole alone.,Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791583/),,0.18,164111,DB01026,Ketoconazole
,19293388,bioavailability,This increased apparent oral clearance was a result of an increased systemic clearance (1.9-fold) and a decreased bioavailability (approximately 45%) during pregnancy.,"As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate Macaca nemestrina. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293388/),%,45,165197,DB01026,Ketoconazole
,22114028,inhibitory concentration (IC)(50),"In rat liver microsomes, inhibitory concentration (IC)(50) of BBR inhibiting KTZ depletion was determined to be 103 µm.",Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114028/),µm,103,166686,DB01026,Ketoconazole
,30779479,effective half-life (t1/2(eff) ),"In the SAD study (400-1600 mg, SBF), mean effective half-life (t1/2(eff) ) of JTK-853 was 8.3 to 10.9 hours, and 20.3 to 27.3 hours in the MAD study (twice daily dosing, fed condition), with 2- to 3-fold accumulation in exposure (AUCtau ).","Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779479/),h,8.3 to 10.9,167112,DB01026,Ketoconazole
,30779479,effective half-life (t1/2(eff) ),"In the SAD study (400-1600 mg, SBF), mean effective half-life (t1/2(eff) ) of JTK-853 was 8.3 to 10.9 hours, and 20.3 to 27.3 hours in the MAD study (twice daily dosing, fed condition), with 2- to 3-fold accumulation in exposure (AUCtau ).","Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779479/),h,20.3 to 27.3,167113,DB01026,Ketoconazole
,18647303,K(m),Maraviroc was metabolized to its N-dealkylated product via a single CYP enzyme characterized by a K(m) of 21 microM and V(max) of 0.45 pmol pmol(-1) min(-1) in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor).,Maraviroc: in vitro assessment of drug-drug interaction potential. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),μM,21,169385,DB01026,Ketoconazole
,18647303,V(max),Maraviroc was metabolized to its N-dealkylated product via a single CYP enzyme characterized by a K(m) of 21 microM and V(max) of 0.45 pmol pmol(-1) min(-1) in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor).,Maraviroc: in vitro assessment of drug-drug interaction potential. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),[pM] / [min·pmol],0.45,169386,DB01026,Ketoconazole
,18647303,K(m),"Using recombinant CYP3A4, N-dealkylation was characterized by a K(m) of 13 microM and a V(max) of 3 pmol pmol(-1) CYP min(-1).",Maraviroc: in vitro assessment of drug-drug interaction potential. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),μM,13,169387,DB01026,Ketoconazole
,18647303,V(max),"Using recombinant CYP3A4, N-dealkylation was characterized by a K(m) of 13 microM and a V(max) of 3 pmol pmol(-1) CYP min(-1).",Maraviroc: in vitro assessment of drug-drug interaction potential. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),[cyp·pM] / [min·pmol],3,169388,DB01026,Ketoconazole
,15671557,survival,Median survival was 14.6 months.,"A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671557/),month,14.6,171334,DB01026,Ketoconazole
,8627582,absolute bioavailability,The absolute bioavailability of oral tirilazad was 8.7 +/- 4.8%; ketoconazole increased the bioavailability to 20.9 +/- 6.5%.,Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8627582/),%,8.7,172768,DB01026,Ketoconazole
,8627582,bioavailability,The absolute bioavailability of oral tirilazad was 8.7 +/- 4.8%; ketoconazole increased the bioavailability to 20.9 +/- 6.5%.,Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8627582/),%,20.9,172769,DB01026,Ketoconazole
,11334355,extraction recoveries,"The extraction recoveries for ketoconazole and clotrimazole in human plasma were 93+/-9.7% and 83+/-10.0%, respectively.","Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334355/),%,93,174868,DB01026,Ketoconazole
,11334355,extraction recoveries,"The extraction recoveries for ketoconazole and clotrimazole in human plasma were 93+/-9.7% and 83+/-10.0%, respectively.","Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334355/),%,83,174869,DB01026,Ketoconazole
,7910724,area under the concentration-time curve,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[h·μg] / [ml],78.12,175099,DB01026,Ketoconazole
,7910724,area under the concentration-time curve,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[h·μg] / [ml],59.32,175100,DB01026,Ketoconazole
,7910724,maximal concentration,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[μg] / [ml],12.34,175101,DB01026,Ketoconazole
,7910724,maximal concentration,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[μg] / [ml],8.92,175102,DB01026,Ketoconazole
,10745059,K(m),Formation of mCPP from trazodone in liver microsomes had a mean (+/- SE) K(m) value of 163 (+/- 21) micromol/L.,In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],163,176334,DB01026,Ketoconazole
,10745059,inhibition constant (K(i)),"Ketoconazole, a relatively specific CYP3A inhibitor, impaired mCPP formation consistent with a competitive mechanism, having an inhibition constant (K(i)) of 0.12 (+/- 0.01) micromol/L.",In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],0.12,176335,DB01026,Ketoconazole
,10745059,K(m),"Among heterologously expressed human cytochromes, only CYP3A4 mediated formation of mCPP from trazodone; the K(m) was 180 micromol/L, consistent with the value in microsomes.",In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],180,176336,DB01026,Ketoconazole
,10745059,K(i),The HIVPI ritonavir was a potent inhibitor of mCPP formation in liver microsomes (K(i) = 0.14 +/- 0.04 micromol/L).,In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],0.14,176337,DB01026,Ketoconazole
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2791,176461,DB01026,Ketoconazole
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2069,176462,DB01026,Ketoconazole
,1596283,IC50,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,7.5,176859,DB01026,Ketoconazole
,1596283,Ki,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,11.2,176860,DB01026,Ketoconazole
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,17.5,176861,DB01026,Ketoconazole
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,122,176862,DB01026,Ketoconazole
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,8.6,176863,DB01026,Ketoconazole
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,28.5,176864,DB01026,Ketoconazole
,19931997,retention times,The retention times of nutlin-3a and ketoconazole were 1.14 and 1.45min.,Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),min,1.14,176926,DB01026,Ketoconazole
,19931997,retention times,The retention times of nutlin-3a and ketoconazole were 1.14 and 1.45min.,Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),min,1.45,176927,DB01026,Ketoconazole
,19931997,recoveries,"The mean recoveries for PP and LLE were 24% and 78%, respectively.",Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),%,24,176928,DB01026,Ketoconazole
,19931997,recoveries,"The mean recoveries for PP and LLE were 24% and 78%, respectively.",Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),%,78,176929,DB01026,Ketoconazole
,29338933,Ki,The estimated in vivo Ki of ketoconazole for hepatic CYP3A4 (6.64 ng/mL) was consistent with the reported values.,Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],6.64,177393,DB01026,Ketoconazole
,29338933,Ki,"The in vivo Ki of ketoconazole for renal P-gp was successfully estimated as 2.27 ng/mL, which was notably lower than reported in vitro 50% inhibitory concentration (IC50) values ranged 223-2440 ng/mL due to different condition between in vitro and in vivo.",Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],2.27,177394,DB01026,Ketoconazole
,29338933,50% inhibitory concentration (IC50),"The in vivo Ki of ketoconazole for renal P-gp was successfully estimated as 2.27 ng/mL, which was notably lower than reported in vitro 50% inhibitory concentration (IC50) values ranged 223-2440 ng/mL due to different condition between in vitro and in vivo.",Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],223-2440,177395,DB01026,Ketoconazole
,21496064,terminal half-life (t(1/2) ),"Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h.","Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,11.4,177627,DB01026,Ketoconazole
,21496064,terminal half-life (t(1/2) ),"Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h.","Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,15.3,177628,DB01026,Ketoconazole
,21496064,terminal half-life,The terminal half-life was slightly increased from 10.5 h to 11.8 h.,"Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,10.5,177629,DB01026,Ketoconazole
,21496064,terminal half-life,The terminal half-life was slightly increased from 10.5 h to 11.8 h.,"Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,11.8,177630,DB01026,Ketoconazole
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,3.9,178571,DB01026,Ketoconazole
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,1.1,178572,DB01026,Ketoconazole
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,4.4,178573,DB01026,Ketoconazole
,2698437,half-life,"Mean half-life of Rifampicin was 3.5 +/- 0.8 and 4.2 +/- 1.1 hs, respectively, when it was given alone and concurrently.","[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,3.5,178574,DB01026,Ketoconazole
,2698437,half-life,"Mean half-life of Rifampicin was 3.5 +/- 0.8 and 4.2 +/- 1.1 hs, respectively, when it was given alone and concurrently.","[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,4.2,178575,DB01026,Ketoconazole
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [h·kg],1.16,180537,DB01026,Ketoconazole
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [h·kg],0.96,180538,DB01026,Ketoconazole
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,16.7,180539,DB01026,Ketoconazole
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,19.2,180540,DB01026,Ketoconazole
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[h·nM] / [l],3507,180541,DB01026,Ketoconazole
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[h·nM] / [l],3180,180542,DB01026,Ketoconazole
> or =,16122280,Absorption,Absorption of telithromycin in humans is estimated to be > or = 90%.,"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),%,90,180625,DB01026,Ketoconazole
,16122280,absolute bioavailability,Its absolute bioavailability is 57% and is unaffected by food.,"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),%,57,180626,DB01026,Ketoconazole
,16122280,volume of distribution,The volume of distribution of telithromycin after intravenous infusion is 2.9 L/kg.,"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),[l] / [kg],2.9,180627,DB01026,Ketoconazole
,16122280,peak plasma concentration,"In healthy subjects receiving telithromycin 800 mg once daily, the peak plasma concentration achieved is 2.27 microg/mL.","Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),[μg] / [ml],2.27,180628,DB01026,Ketoconazole
,16122280,disposition half-life,"Plasma concentrations of telithromycin show a biphasic decrease over time, with an initial disposition half-life of 2.9 hours and a terminal elimination half-life of approximately 10 hours after multiple dose administration.","Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),h,2.9,180629,DB01026,Ketoconazole
,16122280,terminal elimination half-life,"Plasma concentrations of telithromycin show a biphasic decrease over time, with an initial disposition half-life of 2.9 hours and a terminal elimination half-life of approximately 10 hours after multiple dose administration.","Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),h,10,180630,DB01026,Ketoconazole
,10582742,systemic,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),[ml] / [kg·min],2.73,183205,DB01026,Ketoconazole
,10582742,systemic,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),[ml] / [kg·min],1.22,183206,DB01026,Ketoconazole
,10582742,terminal phase half-life,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),h,10.7,183207,DB01026,Ketoconazole
,10582742,terminal phase half-life,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),h,22.2,183208,DB01026,Ketoconazole
,1428196,peak plasma concentration (Cmax),"This occurred when the drug concentrations in cauda epididymal fluid and seminal plasma were at their peak (18.0 +/- 7.3 and 13.5 +/- 3.0 micrograms ml-1, respectively), and which was preceded by a peak plasma concentration (Cmax) of 64.82 +/- 2.47 micrograms ml-1 at 5.15 +/- 0.68 h (Tmax).",Pharmacokinetic and pharmacodynamic studies of the effect of ketoconazole on reproductive function in male rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428196/),[μg] / [ml],64.82,183380,DB01026,Ketoconazole
,1428196,Tmax,"This occurred when the drug concentrations in cauda epididymal fluid and seminal plasma were at their peak (18.0 +/- 7.3 and 13.5 +/- 3.0 micrograms ml-1, respectively), and which was preceded by a peak plasma concentration (Cmax) of 64.82 +/- 2.47 micrograms ml-1 at 5.15 +/- 0.68 h (Tmax).",Pharmacokinetic and pharmacodynamic studies of the effect of ketoconazole on reproductive function in male rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428196/),h,5.15,183381,DB01026,Ketoconazole
,23298433,AUC/MIC ratios,"Moreover, integration of in vivo pharmacokinetic data with the in vitro minimum inhibitory concentration (MIC) provided iodiconazole AUC/MIC ratios in rat dermis and blood of 347.7h and 18.8h, respectively, with an iodiconazole cream (2%) dosage of 0.033 g/cm² (3 cm×5 cm).","In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298433/),h,347.7,185112,DB01026,Ketoconazole
,23298433,AUC/MIC ratios,"Moreover, integration of in vivo pharmacokinetic data with the in vitro minimum inhibitory concentration (MIC) provided iodiconazole AUC/MIC ratios in rat dermis and blood of 347.7h and 18.8h, respectively, with an iodiconazole cream (2%) dosage of 0.033 g/cm² (3 cm×5 cm).","In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298433/),h,18.8,185113,DB01026,Ketoconazole
,27734291,terminal plasma half-life,Cabozantinib displays a long terminal plasma half-life (~120 h) and accumulates ~fivefold by day 15 following daily dosing based on area under the plasma concentration-time curve (AUC).,Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734291/),h,120,185601,DB01026,Ketoconazole
,29498947,Bioavailability,"Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing.",Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),%,52,187661,DB01026,Ketoconazole
,29498947,Bioavailability,"Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing.",Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),%,35,187662,DB01026,Ketoconazole
,29498947,Time for concentrations to decrease 50% from maximal,Time for concentrations to decrease 50% from maximal values was similar after 1 dose (2.5 ± 0.85 h) and 12 doses (2.5 ± 0.72 h).,Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),h,2.5,187663,DB01026,Ketoconazole
,29498947,Time for concentrations to decrease 50% from maximal,Time for concentrations to decrease 50% from maximal values was similar after 1 dose (2.5 ± 0.85 h) and 12 doses (2.5 ± 0.72 h).,Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),h,2.5,187664,DB01026,Ketoconazole
,15792396,"maximal telithromycin concentration at steady state (C(max),ss)","In subjects with CL(CR) 30 - 80 ml/min, the mean maximal telithromycin concentration at steady state (C(max),ss) was 3.6 mg/l and the steady state area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24 h) ss) was 33.4 mg x h/l.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[mg] / [l],3.6,188152,DB01026,Ketoconazole
,15792396,steady state area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24 h) ss),"In subjects with CL(CR) 30 - 80 ml/min, the mean maximal telithromycin concentration at steady state (C(max),ss) was 3.6 mg/l and the steady state area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24 h) ss) was 33.4 mg x h/l.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[h·mg] / [l],33.4,188153,DB01026,Ketoconazole
,15792396,"C(max), ss","The mean C(max), ss and AUC(0-12 h)ss for clarithromycin were 6.2 mg/l and 56.1 mg x h/l, respectively.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[mg] / [l],6.2,188154,DB01026,Ketoconazole
,15792396,AUC(0-12 h)ss,"The mean C(max), ss and AUC(0-12 h)ss for clarithromycin were 6.2 mg/l and 56.1 mg x h/l, respectively.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[h·mg] / [l],56.1,188155,DB01026,Ketoconazole
<,15792396,deltaQTc,In the telithromycin plus ketoconazole group deltaQTc values were equal or < 60 ms.,Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),ms,60,188156,DB01026,Ketoconazole
<,15792396,QTc,All QTc values were equal or < 450 ms in males and equal or < 470 ms in females.,Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),ms,450,188157,DB01026,Ketoconazole
<,15792396,QTc,All QTc values were equal or < 450 ms in males and equal or < 470 ms in females.,Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),ms,470,188158,DB01026,Ketoconazole
,10801241,50% inhibitory concentration,The 50% inhibitory concentration was 0.11 micromol/L (0.08 microg/mL); this is below the usual therapeutic plasma concentration range (generally exceeding 2 microg/mL).,Alprazolam-ritonavir interaction: implications for product labeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801241/),[μM] / [l],0.11,188544,DB01026,Ketoconazole
,10801241,elimination half-life,"In the clinical study, ritonavir reduced alprazolam clearance to 41% of control values (P < .001), prolonged elimination half-life (mean values, 30 versus 13 hours; P < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Alprazolam-ritonavir interaction: implications for product labeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801241/),h,30,188545,DB01026,Ketoconazole
,10801241,elimination half-life,"In the clinical study, ritonavir reduced alprazolam clearance to 41% of control values (P < .001), prolonged elimination half-life (mean values, 30 versus 13 hours; P < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Alprazolam-ritonavir interaction: implications for product labeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801241/),h,13,188546,DB01026,Ketoconazole
,9765344,area under the curve,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],9.4,191639,DB01026,Ketoconazole
,9765344,area under the curve,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],102,191640,DB01026,Ketoconazole
,9765344,oral plasma clearance,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],3810,191641,DB01026,Ketoconazole
,9765344,oral plasma clearance,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],306,191642,DB01026,Ketoconazole
,9765344,AUC,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],94,191643,DB01026,Ketoconazole
,9765344,AUC,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],107,191644,DB01026,Ketoconazole
,9765344,clearance,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],110,191645,DB01026,Ketoconazole
,9765344,clearance,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],95,191646,DB01026,Ketoconazole
,9765344,oral bioavailability,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),%,2.9,191647,DB01026,Ketoconazole
,9765344,oral bioavailability,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),%,31.0,191648,DB01026,Ketoconazole
,6282204,half life,The half life ranged from 2.0 to 3.3 h.,"Disposition of ketoconazole, an oral antifungal, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),h,2.0 to 3.3,192001,DB01026,Ketoconazole
up to,6282204,Peak serum concentrations,"Peak serum concentrations up to 50 micrograms/ml were detected in this study, and potentially therapeutic concentrations were detectable up to 26 h after high doses.","Disposition of ketoconazole, an oral antifungal, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),[μg] / [ml],50,192002,DB01026,Ketoconazole
,23580936,entrapment efficiency,The entrapment efficiency was found in the range of 55.14 ± 2.29-78.63 ± 0.91% and in vitro drug release in the range of 46.63 ± 0.95-72.37 ± 0.59% in 24 h.,Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23580936/),%,55.14,192846,DB01026,Ketoconazole
,23580936,entrapment efficiency,The entrapment efficiency was found in the range of 55.14 ± 2.29-78.63 ± 0.91% and in vitro drug release in the range of 46.63 ± 0.95-72.37 ± 0.59% in 24 h.,Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23580936/),%,78.63,192847,DB01026,Ketoconazole
,23580936,drug release,The entrapment efficiency was found in the range of 55.14 ± 2.29-78.63 ± 0.91% and in vitro drug release in the range of 46.63 ± 0.95-72.37 ± 0.59% in 24 h.,Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23580936/),%,46.63,192848,DB01026,Ketoconazole
,23580936,drug release,The entrapment efficiency was found in the range of 55.14 ± 2.29-78.63 ± 0.91% and in vitro drug release in the range of 46.63 ± 0.95-72.37 ± 0.59% in 24 h.,Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23580936/),%,72.37,192849,DB01026,Ketoconazole
,21209240,kdeg,"In addition, the authors believe that a hepatic CYP3A kdeg of 0.03 h(-1) should be considered for future Simcyp studies.",Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209240/),1/[h],0.03,193945,DB01026,Ketoconazole
,26356245,intestinal availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.45,194246,DB01026,Ketoconazole
,26356245,hepatic availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.31,194247,DB01026,Ketoconazole
,26356245,fraction absorbed,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.89,194248,DB01026,Ketoconazole
,6285814,peak concentrations,"The peak concentrations of ketoconazole attained with brand 1 were 4.1 +/- 0.3 micrograms/ml (mean +/- standard error of the mean) after fasting, 2.3 +/- 0.3 micrograms/ml after the standardized meal (P less than 0.01), and 3.6 +/- 0.2 micrograms/ml with orange juice.",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],4.1,196797,DB01026,Ketoconazole
,6285814,peak concentrations,"The peak concentrations of ketoconazole attained with brand 1 were 4.1 +/- 0.3 micrograms/ml (mean +/- standard error of the mean) after fasting, 2.3 +/- 0.3 micrograms/ml after the standardized meal (P less than 0.01), and 3.6 +/- 0.2 micrograms/ml with orange juice.",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],2.3,196798,DB01026,Ketoconazole
,6285814,peak concentrations,"The peak concentrations of ketoconazole attained with brand 1 were 4.1 +/- 0.3 micrograms/ml (mean +/- standard error of the mean) after fasting, 2.3 +/- 0.3 micrograms/ml after the standardized meal (P less than 0.01), and 3.6 +/- 0.2 micrograms/ml with orange juice.",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],3.6,196799,DB01026,Ketoconazole
,6285814,areas under the serum concentration-time curves,"The peak concentrations were reached in 1.4, 2.3 (P less than 0.05), and 1.8 h, respectively, whereas the areas under the serum concentration-time curves were 14.4 +/- 2.21, 8.6 +/- 1.33 (P less than 0.05), and 13.4 +/- 1.30 micrograms.h/ml, respectively.",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],14.4,196800,DB01026,Ketoconazole
,6285814,areas under the serum concentration-time curves,"The peak concentrations were reached in 1.4, 2.3 (P less than 0.05), and 1.8 h, respectively, whereas the areas under the serum concentration-time curves were 14.4 +/- 2.21, 8.6 +/- 1.33 (P less than 0.05), and 13.4 +/- 1.30 micrograms.h/ml, respectively.",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],8.6,196801,DB01026,Ketoconazole
,6285814,areas under the serum concentration-time curves,"The peak concentrations were reached in 1.4, 2.3 (P less than 0.05), and 1.8 h, respectively, whereas the areas under the serum concentration-time curves were 14.4 +/- 2.21, 8.6 +/- 1.33 (P less than 0.05), and 13.4 +/- 1.30 micrograms.h/ml, respectively.",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],13.4,196802,DB01026,Ketoconazole
,6285814,half-lives,The half-lives (1.7 to 2 h) did not vary significantly among the different regimens.,Impairing effect of food on ketoconazole absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),h,1.7 to 2,196803,DB01026,Ketoconazole
,6285814,peak concentration,"Compared with ketoconazole, oral absorption of miconazole was poor (peak concentration, 0.47 +/- 0.7 micrograms/ml; time to reach the peak concentration, 2.6 h; area under the serum concentration-time curve, 1.10 +/- 0.20 micrograms.h/ml).",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],0.47,196804,DB01026,Ketoconazole
,6285814,time to reach the peak concentration,"Compared with ketoconazole, oral absorption of miconazole was poor (peak concentration, 0.47 +/- 0.7 micrograms/ml; time to reach the peak concentration, 2.6 h; area under the serum concentration-time curve, 1.10 +/- 0.20 micrograms.h/ml).",Impairing effect of food on ketoconazole absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),h,2.6,196805,DB01026,Ketoconazole
,6285814,area under the serum concentration-time curve,"Compared with ketoconazole, oral absorption of miconazole was poor (peak concentration, 0.47 +/- 0.7 micrograms/ml; time to reach the peak concentration, 2.6 h; area under the serum concentration-time curve, 1.10 +/- 0.20 micrograms.h/ml).",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],1.10,196806,DB01026,Ketoconazole
lower,31505985,bioavailability,Lovastatin shows low bioavailability (lower than 5%) after oral administration because of the poor aqueous solubility and widely metabolized by CYP3A4.,The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31505985/),%,5,197251,DB01026,Ketoconazole
up to,31505985,absolute bioavailability,"The oral bioavailability of lovastatin and lovastatin acid after oral administration of lovastatin solid dispersion with 10 mg/kg kaempferol (CYP3A4 inhibitor) were increased about 3.79-fold and 2.51-fold than that of lovastatin suspension, and the absolute bioavailability of lovastatin was up to 33.0%.",The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31505985/),%,33.0,197252,DB01026,Ketoconazole
>,22149256,oral bioavailability,"Results from these studies have demonstrated that fingolimod is efficiently absorbed, with an oral bioavailability of >90%, and its absorption is unaffected by dietary intake, therefore it can be taken without regard to meals.",Clinical pharmacokinetics of fingolimod. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22149256/),%,90,198853,DB01026,Ketoconazole
,22149256,half-life,"Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 months of daily dosing.",Clinical pharmacokinetics of fingolimod. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22149256/),d,6-9,198854,DB01026,Ketoconazole
,11932959,C(max),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[μg] / [ml],1.12,200255,DB01026,Ketoconazole
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[h·μg] / [ml],5.34,200256,DB01026,Ketoconazole
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[μg] / [ml],2.19,200257,DB01026,Ketoconazole
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[h·μg] / [ml],9.52,200258,DB01026,Ketoconazole
,11932959,T(max),"Ketoconazole increased cyclosporine C(max) and AUC(0-6) by 50-60%, regardless of the vehicle or the cyclosporine dose, without altering T(max) (2-3 h).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),h,2-3,200259,DB01026,Ketoconazole
,2893696,Biliary excretion,Biliary excretion of radioactivity averaged 54.3 +/- 18.0% of the dose over a 7.5-8-hr period in pentobarbital-anesthesized rats.,The disposition and pharmacokinetics of ketoconazole in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),%,54.3,202272,DB01026,Ketoconazole
,2893696,VD,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),[ml] / [kg],655,202273,DB01026,Ketoconazole
,2893696,Cl,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),[ml] / [kg·min],14.4,202274,DB01026,Ketoconazole
,2893696,t 1/2,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),min,35.0,202275,DB01026,Ketoconazole
,2893696,time to peak,"The time to peak was 30-60 min, and the bioavailability was 35.8 +/- 3.55%.",The disposition and pharmacokinetics of ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),min,30-60,202276,DB01026,Ketoconazole
,2893696,bioavailability,"The time to peak was 30-60 min, and the bioavailability was 35.8 +/- 3.55%.",The disposition and pharmacokinetics of ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),%,35.8,202277,DB01026,Ketoconazole
,7648762,peak time,Grapefruit juice postponed the peak time of triazolam from 1.6 hours to 2.5 hours (p < 0.05).,Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648762/),h,1.6,202529,DB01026,Ketoconazole
,7648762,peak time,Grapefruit juice postponed the peak time of triazolam from 1.6 hours to 2.5 hours (p < 0.05).,Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648762/),h,2.5,202530,DB01026,Ketoconazole
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,1.90,202533,DB01026,Ketoconazole
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.35,202534,DB01026,Ketoconazole
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.27,202535,DB01026,Ketoconazole
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,2.80,203765,DB01026,Ketoconazole
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,115,203766,DB01026,Ketoconazole
,25070100,50% inhibitory concentration [IC50],"In human hepatocytes, ketoconazole dose dependently inhibited the formation of N(+)-glucuronides (50% inhibitory concentration [IC50], 1.5 μM), while rifampin induced the mRNA level of UGT1A9 by 28% and the activity of UGT1A9 by 53%.",Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070100/),μM,1.5,203796,DB01026,Ketoconazole
,19011672,AUCS/R ratio,The kinetic disposition of CITA was enantioselective in rats (AUCS/R ratio = 0.4).,"Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19011672/),,0.4,205323,DB01026,Ketoconazole
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,350,206834,DB01026,Ketoconazole
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,11,206835,DB01026,Ketoconazole
,29856004,time to maximum concentration,AZD5069 was rapidly absorbed (time to maximum concentration ~ 2 h) under fasting conditions.,Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856004/),h,2,207364,DB01026,Ketoconazole
,29856004,initial half-life,The plasma concentration of AZD5069 declined with an initial half-life of 4 h and terminal half-life of 11 h.,Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856004/),h,4,207365,DB01026,Ketoconazole
,29856004,terminal half-life,The plasma concentration of AZD5069 declined with an initial half-life of 4 h and terminal half-life of 11 h.,Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856004/),h,11,207366,DB01026,Ketoconazole
,23625188,t ½,Ketoconazole decreased mirabegron t ½ from 50.9 to 37.6 h suggesting that volume of distribution as well as first-pass effect decreased.,"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23625188/),h,50.9,207683,DB01026,Ketoconazole
,23625188,t ½,Ketoconazole decreased mirabegron t ½ from 50.9 to 37.6 h suggesting that volume of distribution as well as first-pass effect decreased.,"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23625188/),h,37.6,207684,DB01026,Ketoconazole
,17523053,time of the peak concentration (T(max)),Imatinib was administered orally or intravenously to dogs and the time of the peak concentration (T(max)) of imatinib was 4-9 h.,Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),h,4-9,207990,DB01026,Ketoconazole
,17523053,half-life,"The mean half-life was 622 +/- 368 min, and the AUC was 1256 +/- 809 microM * min after oral administration.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min,622,207991,DB01026,Ketoconazole
,17523053,AUC,"The mean half-life was 622 +/- 368 min, and the AUC was 1256 +/- 809 microM * min after oral administration.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min·μM,1256,207992,DB01026,Ketoconazole
,17523053,C0,The range of C0 of intravenously injected dogs was 12-24 microM.,Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),μM,12-24,207993,DB01026,Ketoconazole
,17523053,half-life,"The half-life and AUC after intravenous injection were 206 +/- 112 min and 1026 +/- 371 microM * min, respectively.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min,206,207994,DB01026,Ketoconazole
,17523053,AUC,"The half-life and AUC after intravenous injection were 206 +/- 112 min and 1026 +/- 371 microM * min, respectively.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min·μM,1026,207995,DB01026,Ketoconazole
,15373932,elimination half-life,"Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47%[P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4).",Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373932/),h,3.55,208115,DB01026,Ketoconazole
,15373932,elimination half-life,"Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47%[P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4).",Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373932/),h,5.50,208116,DB01026,Ketoconazole
,29626440,Michaels-Menten,Both Michaels-Menten constant Km values for diclofenac 4'-hydroxylation in human and marmoset liver microsomes were ∼30 μM and those for diclofenac 5-hydroxylation were ∼120 μM.,In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626440/),μM,∼30,208233,DB01026,Ketoconazole
,29626440,constant Km,Both Michaels-Menten constant Km values for diclofenac 4'-hydroxylation in human and marmoset liver microsomes were ∼30 μM and those for diclofenac 5-hydroxylation were ∼120 μM.,In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626440/),μM,∼30,208234,DB01026,Ketoconazole
,29626440,constant Km,Both Michaels-Menten constant Km values for diclofenac 4'-hydroxylation in human and marmoset liver microsomes were ∼30 μM and those for diclofenac 5-hydroxylation were ∼120 μM.,In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626440/),μM,∼120,208235,DB01026,Ketoconazole
,12954187,intestinal clearance,"The intestinal clearance of ABZSO was 0.106+/-0.010 ml/min, exhibiting a stereoselective intestinal elimination to (-)ABZSO form.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.106,208940,DB01026,Ketoconazole
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.079,208941,DB01026,Ketoconazole
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.069,208942,DB01026,Ketoconazole
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.065,208943,DB01026,Ketoconazole
,3465533,area under the serum concentration time curve (AUC),The area under the serum concentration time curve (AUC) reached 12.3 +/- 7.7 mg/l.h (mean +/- S.D.) on the 200 mg dose and increased to 23.0 +/- 18.2 mg/l.h on the 400 mg dose (p less than 0.05).,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [h·l],12.3,209074,DB01026,Ketoconazole
,3465533,area under the serum concentration time curve (AUC),The area under the serum concentration time curve (AUC) reached 12.3 +/- 7.7 mg/l.h (mean +/- S.D.) on the 200 mg dose and increased to 23.0 +/- 18.2 mg/l.h on the 400 mg dose (p less than 0.05).,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [h·l],23.0,209075,DB01026,Ketoconazole
,3465533,half-life,The half-life of ketoconazole was 3.1 +/- 1.9 h on the 200 mg dose and 3.5 +/- 1.7 h on the 400 mg dose.,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),h,3.1,209076,DB01026,Ketoconazole
,3465533,half-life,The half-life of ketoconazole was 3.1 +/- 1.9 h on the 200 mg dose and 3.5 +/- 1.7 h on the 400 mg dose.,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),h,3.5,209077,DB01026,Ketoconazole
,3465533,Peak concentrations,"Peak concentrations were 3.2 +/- 1.8 mg/l and 4.6 +/- 3.2 mg/l on the 200 mg and 400 mg doses, respectively.",Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [l],3.2,209078,DB01026,Ketoconazole
,3465533,Peak concentrations,"Peak concentrations were 3.2 +/- 1.8 mg/l and 4.6 +/- 3.2 mg/l on the 200 mg and 400 mg doses, respectively.",Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [l],4.6,209079,DB01026,Ketoconazole
,25733012,AUC,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],6,209817,DB01026,Ketoconazole
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],6,209818,DB01026,Ketoconazole
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],541,209819,DB01026,Ketoconazole
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],47.8,209820,DB01026,Ketoconazole
,3243657,peak values,"In the single-dose study, ketoconazole SL concentrations determined between 80 and 390 min showed mean peak values of 0.74 +/- 0.53 micrograms/ml at intermediate sampling times of about 180 min.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],0.74,211434,DB01026,Ketoconazole
,3243657,maximum mean plasma concentration,The maximum mean plasma concentration of 2.37 +/- 1.26 micrograms/ml occurred at an intermediate sampling time (141 min) as well.,Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],2.37,211435,DB01026,Ketoconazole
,3243657,plasma,"In those patients receiving chronic treatment from 1 to 7 days, the mean plasma and SL concentrations were 1.07 +/- 1.17 micrograms/ml and 0.08 +/- 0.2 micrograms/ml, respectively, while chronic treatment from 15 to 64 days resulted in higher values of 2.22 +/- 1.91 micrograms/ml and 0.56 +/- 0.57 micrograms/ml, respectively.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],1.07,211436,DB01026,Ketoconazole
,3243657,plasma,"In those patients receiving chronic treatment from 1 to 7 days, the mean plasma and SL concentrations were 1.07 +/- 1.17 micrograms/ml and 0.08 +/- 0.2 micrograms/ml, respectively, while chronic treatment from 15 to 64 days resulted in higher values of 2.22 +/- 1.91 micrograms/ml and 0.56 +/- 0.57 micrograms/ml, respectively.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],2.,211437,DB01026,Ketoconazole
,3243657,plasma,"In those patients receiving chronic treatment from 1 to 7 days, the mean plasma and SL concentrations were 1.07 +/- 1.17 micrograms/ml and 0.08 +/- 0.2 micrograms/ml, respectively, while chronic treatment from 15 to 64 days resulted in higher values of 2.22 +/- 1.91 micrograms/ml and 0.56 +/- 0.57 micrograms/ml, respectively.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],0.56,211438,DB01026,Ketoconazole
,18956271,IC(50),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.2,215833,DB01026,Ketoconazole
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,0.5,215834,DB01026,Ketoconazole
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215835,DB01026,Ketoconazole
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.9,215836,DB01026,Ketoconazole
,18956271,IC(50),"Similarly, beauvericin was also a potent inhibitor for CYP3A1/2 (IC(50): 1.3 microM) in RLM.",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215837,DB01026,Ketoconazole
,11510627,time (tmax) to peak concentration (Cmax),"In young healthy volunteers, absorption of mizolastine is rapid with time (tmax) to peak concentration (Cmax) of about 1 hour.",Clinical pharmacokinetics of mizolastine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1,215900,DB01026,Ketoconazole
,11510627,absolute bioavailability,The absolute bioavailability of mizolastine 10mg tablets is about 65%.,Clinical pharmacokinetics of mizolastine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),%,65,215901,DB01026,Ketoconazole
,11510627,distribution half-life,Distribution is rapid with a mean distribution half-life of 1.5 to 1.9 hours.,Clinical pharmacokinetics of mizolastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1.5 to 1.9,215902,DB01026,Ketoconazole
,11510627,apparent volume of distribution,Mizolastine is >98% bound to serum albumin and the apparent volume of distribution is between I and 1.4 L/kg.,Clinical pharmacokinetics of mizolastine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [kg],I and 1.4,215903,DB01026,Ketoconazole
,11510627,terminal elimination half-life (t1/2beta),The terminal elimination half-life (t1/2beta) is 7.3 to 17.1 hours.,Clinical pharmacokinetics of mizolastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,7.3 to 17.1,215904,DB01026,Ketoconazole
,11510627,apparent oral clearance,"The apparent oral clearance after a repeated oral dose of 10mg is 6.02 L/h, with steady state reached from day 3 and no accumulation between days 1 and 7.",Clinical pharmacokinetics of mizolastine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [h],6.02,215905,DB01026,Ketoconazole
,3735080,AUC,In humans the AUC value for Ksol (62.21 +/- 21.2 microgram X h/ml; mean +/- SD) was significantly greater than for Ktab (50.0 +/- 15.2 micrograms X h/ml; p less than 0.05).,Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[h·μg] / [ml],62.21,216184,DB01026,Ketoconazole
,3735080,AUC,In humans the AUC value for Ksol (62.21 +/- 21.2 microgram X h/ml; mean +/- SD) was significantly greater than for Ktab (50.0 +/- 15.2 micrograms X h/ml; p less than 0.05).,Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[h·μg] / [ml],50.0,216185,DB01026,Ketoconazole
,3735080,systemic clearance (CLs),"The mean systemic clearance (CLs) of Kiv in dogs was 2.74 +/- 1.10 mL/min/kg, the volume of distribution at steady state (Vdss) was 0.72 +/- 0.28 L/kg, and the half-life was 2.7 +/- 1.6 h.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[ml] / [kg·min],2.74,216186,DB01026,Ketoconazole
,3735080,volume of distribution at steady state (Vdss),"The mean systemic clearance (CLs) of Kiv in dogs was 2.74 +/- 1.10 mL/min/kg, the volume of distribution at steady state (Vdss) was 0.72 +/- 0.28 L/kg, and the half-life was 2.7 +/- 1.6 h.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[l] / [kg],0.72,216187,DB01026,Ketoconazole
,3735080,half-life,"The mean systemic clearance (CLs) of Kiv in dogs was 2.74 +/- 1.10 mL/min/kg, the volume of distribution at steady state (Vdss) was 0.72 +/- 0.28 L/kg, and the half-life was 2.7 +/- 1.6 h.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),h,2.7,216188,DB01026,Ketoconazole
,3735080,absolute bioavailability,"The absolute bioavailability of Ktab was 0.50 +/- 0.38, which did not differ statistically from that of Ksol, 0.56 +/- 0.23.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),,0.50,216189,DB01026,Ketoconazole
,3735080,absolute bioavailability,"The absolute bioavailability of Ktab was 0.50 +/- 0.38, which did not differ statistically from that of Ksol, 0.56 +/- 0.23.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),,0.56,216190,DB01026,Ketoconazole
,6311786,serum half life,"The serum half life of ketoconazole was 74.8 +/- 13.9 min (mean +/- S.D.) on day 1, and 155.9 +/- 32.7 min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),min,74.8,217367,DB01026,Ketoconazole
,6311786,serum half life,"The serum half life of ketoconazole was 74.8 +/- 13.9 min (mean +/- S.D.) on day 1, and 155.9 +/- 32.7 min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),min,155.9,217368,DB01026,Ketoconazole
,6311786,area under the serum concentration time curve,"On day 1 the area under the serum concentration time curve was 626.9 +/- 230.1 mg/l.min, and 1441 +/- 897.3 mg/l.min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),[mg] / [l·min],626.9,217369,DB01026,Ketoconazole
,6311786,area under the serum concentration time curve,"On day 1 the area under the serum concentration time curve was 626.9 +/- 230.1 mg/l.min, and 1441 +/- 897.3 mg/l.min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),[mg] / [l·min],1441,217370,DB01026,Ketoconazole
,1662191,maximum concentrations (Cmax),At day 7 for ITRA-PEL (n = 8) the mean +/- one standard deviation and median maximum concentrations (Cmax) were 307 +/- 155 ng/mL and 275 ng/mL respectively and for ITRA-PEG (n = 6) 272 +/- 212 ng/mL and 193 ng/mL.,Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],275,218705,DB01026,Ketoconazole
,1662191,maximum concentrations (Cmax),At day 7 for ITRA-PEL (n = 8) the mean +/- one standard deviation and median maximum concentrations (Cmax) were 307 +/- 155 ng/mL and 275 ng/mL respectively and for ITRA-PEG (n = 6) 272 +/- 212 ng/mL and 193 ng/mL.,Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],193,218706,DB01026,Ketoconazole
,1662191,Cmax,"At day 14 for ITRA-PEL (n = 8) the mean +/- S.D. and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL.",Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],375,218707,DB01026,Ketoconazole
,1662191,Cmax,"At day 14 for ITRA-PEL (n = 8) the mean +/- S.D. and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL.",Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],327,218708,DB01026,Ketoconazole
,6322829,area under the plasma concentration time curve (AUC),The area under the plasma concentration time curve (AUC) after the oral dose was 51.41 +/- 10.99 mg l-1 h (mean +/- s.d.) and the half-life of ketoconazole was 2.98 +/- 1.41 h.,Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·mg] / [l],51.41,218791,DB01026,Ketoconazole
,6322829,half-life,The area under the plasma concentration time curve (AUC) after the oral dose was 51.41 +/- 10.99 mg l-1 h (mean +/- s.d.) and the half-life of ketoconazole was 2.98 +/- 1.41 h.,Systemic absorption of ketoconazole from vaginal pessaries. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),h,2.98,218792,DB01026,Ketoconazole
,6322829,AUCs,"The AUCs after vaginal administration were 0.27 +/- 0.14, 0.52 +/- 0.25, and 0.43 +/- 0.22 mg-1 l h following the 400, 800 and 1200 mg pessaries respectively.",Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·l] / [mg],0.27,218793,DB01026,Ketoconazole
,6322829,AUCs,"The AUCs after vaginal administration were 0.27 +/- 0.14, 0.52 +/- 0.25, and 0.43 +/- 0.22 mg-1 l h following the 400, 800 and 1200 mg pessaries respectively.",Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·l] / [mg],0.52,218794,DB01026,Ketoconazole
,6322829,AUCs,"The AUCs after vaginal administration were 0.27 +/- 0.14, 0.52 +/- 0.25, and 0.43 +/- 0.22 mg-1 l h following the 400, 800 and 1200 mg pessaries respectively.",Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·l] / [mg],0.43,218795,DB01026,Ketoconazole
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.,218802,DB01026,Ketoconazole
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.19,218803,DB01026,Ketoconazole
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.06,218804,DB01026,Ketoconazole
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0,218805,DB01026,Ketoconazole
,31145690,AUC ratio,"With the optimized fm values, the predicted AUC ratio was 1.82.","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,1.82,218806,DB01026,Ketoconazole
,9834040,total plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],354,219053,DB01026,Ketoconazole
,9834040,total plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],112,219054,DB01026,Ketoconazole
,9834040,plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],302,219055,DB01026,Ketoconazole
,9834040,half-life (t1/2),"The ropivacaine half-life (t1/2) of 1.9 hours was almost doubled during fluvoxamine administration and the plasma concentration at the end of infusion increased slightly, whereas the corresponding parameters after ketoconazole administration remained unchanged.",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),h,1.9,219056,DB01026,Ketoconazole
,11999755,flow-rate,"Analysis was performed using a Symmetry C18 column (150x4.6 mm, 5 microm) and isocratic elution with 25 mM KH2PO4 (pH 4.5)-acetonitrile (50:50) with a flow-rate of 1 ml/min.",Simple high-performance liquid chromatography method for the simultaneous determination of ketoconazole and piperine in rat plasma and hepatocyte culture. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999755/),[ml] / [min],1,220360,DB01026,Ketoconazole
,11999755,detection limits,"The detection limits for piperine and ketoconazole are 2 and 4 ng, respectively, and the limits of quantitation are 10 and 12 ng, respectively.",Simple high-performance liquid chromatography method for the simultaneous determination of ketoconazole and piperine in rat plasma and hepatocyte culture. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999755/),ng,2,220361,DB01026,Ketoconazole
,11999755,detection limits,"The detection limits for piperine and ketoconazole are 2 and 4 ng, respectively, and the limits of quantitation are 10 and 12 ng, respectively.",Simple high-performance liquid chromatography method for the simultaneous determination of ketoconazole and piperine in rat plasma and hepatocyte culture. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999755/),ng,4,220362,DB01026,Ketoconazole
,7575674,area under the plasma trans-retinoic acid concentration vs time curve,"Treatment with trans-retinoic acid for 1 week reduced the area under the plasma trans-retinoic acid concentration vs time curve in one patient by 67%, from 277 to 91 ng/mL/hr.",Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575674/),[ng] / [h·ml],277,221994,DB01026,Ketoconazole
,7575674,area under the plasma trans-retinoic acid concentration vs time curve,"Treatment with trans-retinoic acid for 1 week reduced the area under the plasma trans-retinoic acid concentration vs time curve in one patient by 67%, from 277 to 91 ng/mL/hr.",Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575674/),[ng] / [h·ml],91,221995,DB01026,Ketoconazole
,7575674,AUC,"Trans-retinoic acid pharmacokinetics were repeated after the second dose of fluconazole, administered 1 hour prior to the retinoid, and the AUC was found to be 401 ng/mL/hr, a greater than 4-fold increase from the pre-fluconazole level.",Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575674/),[ng] / [h·ml],401,221996,DB01026,Ketoconazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],2.94 to,224410,DB01026,Ketoconazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],1,224411,DB01026,Ketoconazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],1.03 to 0.50,224412,DB01026,Ketoconazole
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],3.38 to 0.45,224413,DB01026,Ketoconazole
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],2.65 to 3.36,224414,DB01026,Ketoconazole
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],0.66 to 1.25,224415,DB01026,Ketoconazole
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],3.59 to 10.92,224416,DB01026,Ketoconazole
,8388198,maximum concentration,The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml).,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],140,224495,DB01026,Ketoconazole
,8388198,maximum concentration,The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml).,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],239,224496,DB01026,Ketoconazole
,8388198,terminal half-life,"The rate of elimination was not affected (terminal half-life, approximately 21 h).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),h,21,224497,DB01026,Ketoconazole
,8388198,maximum concentration,"The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],287,224498,DB01026,Ketoconazole
,8388198,maximum concentration,"The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],397,224499,DB01026,Ketoconazole
,8388198,terminal half-life,The terminal half-life of hydroxyitraconazole was approximately 12 h.,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),h,12,224500,DB01026,Ketoconazole
,8388198,steady-state concentrations,"The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole.",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],"1,900",224501,DB01026,Ketoconazole
,8388198,steady-state concentrations,"The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole.",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],"3,200",224502,DB01026,Ketoconazole
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,10.6,224594,DB01026,Ketoconazole
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,170,224595,DB01026,Ketoconazole
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,0.180,224596,DB01026,Ketoconazole
,9179989,elimination half-life,"After i.v. administration of SC-52151 to the female beagle dog (2.5 mg/kg), SC-52151 was rapidly eliminated in plasma with an elimination half-life of about 1 h, a plasma clearance of 44 ml/min/kg and an apparent steady-state volume distribution of 2.2 litre/kg.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),h,1,225348,DB01026,Ketoconazole
,9179989,plasma clearance,"After i.v. administration of SC-52151 to the female beagle dog (2.5 mg/kg), SC-52151 was rapidly eliminated in plasma with an elimination half-life of about 1 h, a plasma clearance of 44 ml/min/kg and an apparent steady-state volume distribution of 2.2 litre/kg.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[ml] / [kg·min],44,225349,DB01026,Ketoconazole
,9179989,apparent steady-state volume distribution,"After i.v. administration of SC-52151 to the female beagle dog (2.5 mg/kg), SC-52151 was rapidly eliminated in plasma with an elimination half-life of about 1 h, a plasma clearance of 44 ml/min/kg and an apparent steady-state volume distribution of 2.2 litre/kg.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[l] / [kg],2.2,225350,DB01026,Ketoconazole
,9179989,bioavailability,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),%,4.1,225351,DB01026,Ketoconazole
,9179989,bioavailability,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),%,9.6,225352,DB01026,Ketoconazole
,9179989,Cmax,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[μg] / [ml],0.41,225353,DB01026,Ketoconazole
,9179989,Cmax,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[μg] / [ml],0.83,225354,DB01026,Ketoconazole
,9179989,absolute bioavailability,"4. Although the absolute bioavailability of SC-52151 was still low (approximately 10%), the Cmax and AUC achieved in this study were satisfactory for conducting chronic toxicology studies.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),%,10,225355,DB01026,Ketoconazole
,26116989,depletion rate constant (kdep),We found that the plasma levels of the (-)-isomer were significantly lower than those of the (+)-enantiomer following i.v. administration of (±)-DOX to the rats and that the depletion rate constant (kdep) of (-)-DOX (0.0107±0.0007L/min) was significantly larger than that of (+)-DOX (kdep 0.0088±0.0005L/min) (p<0.05) when (±)-DOX was incubated with rat liver microsomes (RLMs).,The truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116989/),[l] / [min],0.0107,226014,DB01026,Ketoconazole
,26116989,kdep,We found that the plasma levels of the (-)-isomer were significantly lower than those of the (+)-enantiomer following i.v. administration of (±)-DOX to the rats and that the depletion rate constant (kdep) of (-)-DOX (0.0107±0.0007L/min) was significantly larger than that of (+)-DOX (kdep 0.0088±0.0005L/min) (p<0.05) when (±)-DOX was incubated with rat liver microsomes (RLMs).,The truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26116989/),[l] / [min],0.0088,226015,DB01026,Ketoconazole
,15762767,half-life,The compound has a half-life of approximately 3 hours.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),h,3,226151,DB01026,Ketoconazole
,15762767,absolute bioavailability,Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69.1%.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),%,69.1,226152,DB01026,Ketoconazole
,15355126,systemic availability,A low systemic availability of 9-21% indicates extensive first-pass elimination.,Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355126/),%,9-21,227652,DB01026,Ketoconazole
,7628178,clearance,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [h·kg],0.18,228240,DB01026,Ketoconazole
,7628178,clearance,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [h·kg],0.32,228241,DB01026,Ketoconazole
,7628178,oral bioavailability,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,56.4,228242,DB01026,Ketoconazole
,7628178,oral bioavailability,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,22.4,228243,DB01026,Ketoconazole
,7628178,Steady-state volume of distribution,Steady-state volume of distribution for intravenously administered cyclosporine was unchanged (1.26 +/- 0.44 L/kg versus 1.10 +/- 0.27 L/kg).,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [kg],1.26,228244,DB01026,Ketoconazole
,7628178,Steady-state volume of distribution,Steady-state volume of distribution for intravenously administered cyclosporine was unchanged (1.26 +/- 0.44 L/kg versus 1.10 +/- 0.27 L/kg).,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [kg],1.10,228245,DB01026,Ketoconazole
,7628178,Hepatic bioavailability (1 - hepatic extraction ratio),"Hepatic bioavailability (1 - hepatic extraction ratio) calculated for intravenous cyclosporine increased by 11% in the presence of ketoconazole (86.3% +/- 3.7% versus 75.2% +/- 6.6% without ketoconazole), which accounts for only one third of the observed increase in cyclosporine oral bioavailability.",The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,86.3,228246,DB01026,Ketoconazole
,7628178,Hepatic bioavailability (1 - hepatic extraction ratio),"Hepatic bioavailability (1 - hepatic extraction ratio) calculated for intravenous cyclosporine increased by 11% in the presence of ketoconazole (86.3% +/- 3.7% versus 75.2% +/- 6.6% without ketoconazole), which accounts for only one third of the observed increase in cyclosporine oral bioavailability.",The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,75.2,228247,DB01026,Ketoconazole
,33393940,Half maximal inhibitory concentration,"Half maximal inhibitory concentration values of MenoAct851 on CYP3A4 and CYP2D6 were 11.96 (1.04) µg/mL and 15.24 (0.58) µg/mL, respectively, but they were higher than respective positive controls.","Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33393940/),[μg] / [ml],11.96,228319,DB01026,Ketoconazole
,33393940,Half maximal inhibitory concentration,"Half maximal inhibitory concentration values of MenoAct851 on CYP3A4 and CYP2D6 were 11.96 (1.04) µg/mL and 15.24 (0.58) µg/mL, respectively, but they were higher than respective positive controls.","Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33393940/),[μg] / [ml],15.24,228320,DB01026,Ketoconazole
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.45,229623,DB01026,Ketoconazole
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.39,229624,DB01026,Ketoconazole
,11498244,clearance,The clearance of CsA decreased from a mean (95% CI) of 9.47 (6.2-12.7)ml/min/kg after a single (first) dose (3mg/kg i.v.) to 1.62 (1.38-1.86)ml/min/kg after 18 days of CsA (3mg/kg i.v. twice daily) co-administration with ketoconazole.,Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[ml] / [kg·min],9.47,229794,DB01026,Ketoconazole
,11498244,clearance,The clearance of CsA decreased from a mean (95% CI) of 9.47 (6.2-12.7)ml/min/kg after a single (first) dose (3mg/kg i.v.) to 1.62 (1.38-1.86)ml/min/kg after 18 days of CsA (3mg/kg i.v. twice daily) co-administration with ketoconazole.,Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[ml] / [kg·min],1.62,229795,DB01026,Ketoconazole
,11498244,trough concentration,"Provided that the trough concentration of blood CsA was maintained between 1500-2500 mg/l, long-term healthy skin allografts were maintained on the sheep without significant adverse effects on haematological or biochemical parameters.",Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[mg] / [l],1500-2500,229796,DB01026,Ketoconazole
>,16207309,oral bioavailability,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,70,230489,DB01026,Ketoconazole
>,16207309,elimination half-life,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,20,230490,DB01026,Ketoconazole
,16207309,elimination half-life,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,1.75,230491,DB01026,Ketoconazole
,16207309,volume of distribution,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[l] / [kg],3.46,230492,DB01026,Ketoconazole
,16207309,clearance,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[ml] / [min],25.14,230493,DB01026,Ketoconazole
,16207309,bioavailability,"Following administration with ketoconazole, detectable concentrations of methadone were present in one dog with a 29% bioavailability.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,29,230494,DB01026,Ketoconazole
,16775418,clearance,"Docetaxel clearance was reduced by 50% (P = .018) from 32.8 +/- 13.7 L/hr to 16.5 +/- 8.15 L/hr upon ketoconazole coadministration, albeit with large inter-individual variability (fractional change in clearance, range 0.31 - 0.66).",Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775418/),[l] / [h],32.8,230542,DB01026,Ketoconazole
,16775418,clearance,"Docetaxel clearance was reduced by 50% (P = .018) from 32.8 +/- 13.7 L/hr to 16.5 +/- 8.15 L/hr upon ketoconazole coadministration, albeit with large inter-individual variability (fractional change in clearance, range 0.31 - 0.66).",Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775418/),[l] / [h],16.5,230543,DB01026,Ketoconazole
,25047497,Cmax,"The mean (SD) Cmax values of lobeglitazone with and without ketoconazole were 49 (7) ng/mL and 48 (6) ng/mL at 1.5 and 1.0 hours after dosing, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[ng] / [ml],49,230724,DB01026,Ketoconazole
,25047497,Cmax,"The mean (SD) Cmax values of lobeglitazone with and without ketoconazole were 49 (7) ng/mL and 48 (6) ng/mL at 1.5 and 1.0 hours after dosing, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[ng] / [ml],48,230725,DB01026,Ketoconazole
,25047497,AUC∞,"The mean (SD) AUC∞ values were 532 (117) ng·h/mL and 405 (110) ng·h/mL, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[h·ng] / [ml],532,230726,DB01026,Ketoconazole
,25047497,AUC∞,"The mean (SD) AUC∞ values were 532 (117) ng·h/mL and 405 (110) ng·h/mL, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[h·ng] / [ml],405,230727,DB01026,Ketoconazole
,11295678,half-life,"Desloratadine is rapidly absorbed, has dose-proportional pharmacokinetics, and has a half-life of 27 hours.","Desloratadine: A new, nonsedating, oral antihistamine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295678/),h,27,230937,DB01026,Ketoconazole
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],242,233774,DB01026,Ketoconazole
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],42,233775,DB01026,Ketoconazole
,12183684,clearance,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),[ml] / [kg·min],79 to 55,234910,DB01026,Ketoconazole
,12183684,clearance,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),[ml] / [kg·min],1051 to 237,234911,DB01026,Ketoconazole
,12183684,absolute bioavailability,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),,0.11,234912,DB01026,Ketoconazole
,12183684,absolute bioavailability,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),,0.36,234913,DB01026,Ketoconazole
,15842554,K(m),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),μm,121.7,235078,DB01026,Ketoconazole
,15842554,V(max),"In human liver microsomal incubation studies, the formation of 2-hydroxychlorpropamide (2-OH-chlorpropamide), a major chlorpropamide metabolite in human, has been best described by a one-enzyme model with estimated K(m) and V(max) of 121.7 +/- 19.9 microm and 16.1 +/- 5.0 pmol min(-1) mg(-1) protein, respectively.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[pM] / [mg·min],16.1,235079,DB01026,Ketoconazole
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[μl] / [min·nmol],0.26,235080,DB01026,Ketoconazole
,15842554,intrinsic clearances,"In incubation studies using human recombinant CYP isoforms, however, 2-OH-chlorpropamide was formed by both CYP2C9 and CYP2C19 with similar intrinsic clearances (CYP2C9 vs. CYP2C19: 0.26 vs. 0.22 microl min(-1) nmol(-1) protein).","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),[μl] / [min·nmol],0.22,235081,DB01026,Ketoconazole
,15842554,nonrenal clearance,"In in vivo clinical trials, eight subjects with the CYP2C9*1/*3 genotype exhibited significantly lower nonrenal clearance [*1/*3 vs.*1/*1: 1.8 +/- 0.2 vs.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.8,235082,DB01026,Ketoconazole
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,1.01,235083,DB01026,Ketoconazole
,15842554,metabolic ratios,"2.4 +/- 0.1 ml h(-1) kg(-1), P < 0.05; 95% confidence interval (CI) on the difference 0.2, 1.0] and higher metabolic ratios (of chlorpropamide/2-OH-chlorpropamide in urine: *1/*3 vs.*1/*1: 1.01 +/- 0.19 vs. 0.56 +/- 0.08, P < 0.05; 95% CI on the difference - 0.9, - 0.1) than did 13 subjects with CYP2C9*1/*1 genotype.","Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15842554/),,0.56,235084,DB01026,Ketoconazole
,19566113,absolute bioavailability,"The absolute bioavailability is 20-25%, and administration of cinacalcet with low- or high-fat meals increases exposure (area under the plasma concentration-time curve from time zero to infinity [AUC(infinity)]) 1.5- to 1.8-fold.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),%,20-25,235608,DB01026,Ketoconazole
,19566113,terminal elimination half-life,"The terminal elimination half-life is 30-40 hours, and steady-state concentrations are achieved within 7 days.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),h,30-40,235609,DB01026,Ketoconazole
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],600,237179,DB01026,Ketoconazole
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],900,237180,DB01026,Ketoconazole
,20683390,elimination half-life,The elimination half-life of sotrastaurin averages 6 hours.,Overview of sotrastaurin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),h,6,237181,DB01026,Ketoconazole
,12723463,AUC,"Ketoconazole coadministration increased mean almotriptan AUC and Cmax from 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively.",Interaction between ketoconazole and almotriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[h·ng] / [ml],312 to 490,238911,DB01026,Ketoconazole
,12723463,Cmax,"Ketoconazole coadministration increased mean almotriptan AUC and Cmax from 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively.",Interaction between ketoconazole and almotriptan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[ng] / [ml],52.6 to 84.5,238912,DB01026,Ketoconazole
,12723463,oral clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],40,238913,DB01026,Ketoconazole
,12723463,oral clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],26,238914,DB01026,Ketoconazole
,12723463,renal clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],16.4 to 13.8,238915,DB01026,Ketoconazole
,2731510,peak serum ketoconazole concentration,Mean peak serum ketoconazole concentration was 3.76 micrograms/ml at 1.5 to 2 h after intragastric administration.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],3.76,238921,DB01026,Ketoconazole
,2731510,peak synovial concentration,Mean peak synovial concentration was 0.87 micrograms/ml 3 h after the fifth dose.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],0.87,238922,DB01026,Ketoconazole
,2731510,peritoneal concentration,"Similarly, mean peritoneal concentration peaked 3 h after the fifth dose at 1.62 micrograms/ml.",Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],1.62,238923,DB01026,Ketoconazole
,2731510,endometrial,Mean endometrial concentrations peaked at 2.73 micrograms/ml 2 h after the fifth dose.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],2.73,238924,DB01026,Ketoconazole
,2731510,concentrations,Mean endometrial concentrations peaked at 2.73 micrograms/ml 2 h after the fifth dose.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],2.73,238925,DB01026,Ketoconazole
,2731510,overall elimination rate constant,A single intravenous injection of ketoconazole (10 mg/kg bwt) was given to one of the six mares; the overall elimination rate constant was estimated at 0.22/h and bioavailability after oral administration was 23 per cent.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),1/[h],0.22,238926,DB01026,Ketoconazole
,2731510,bioavailability,A single intravenous injection of ketoconazole (10 mg/kg bwt) was given to one of the six mares; the overall elimination rate constant was estimated at 0.22/h and bioavailability after oral administration was 23 per cent.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),%,23,238927,DB01026,Ketoconazole
,9812178,t1/2 beta,The clinically relevant t1/2 beta is about 3 to 5 hours.,Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),h,3 to 5,239662,DB01026,Ketoconazole
,9812178,apparent oral clearance,"The pharmacokinetics of ritonavir are relatively linear after multiple doses, with apparent oral clearance averaging 7 to 9 L/h.",Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),[l] / [h],7 to 9,239663,DB01026,Ketoconazole
,8632299,Vmax,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[nM] / [mg·min],10.3,240628,DB01026,Ketoconazole
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,304,240629,DB01026,Ketoconazole
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,2.4,240630,DB01026,Ketoconazole
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,74,240631,DB01026,Ketoconazole
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.006,240632,DB01026,Ketoconazole
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.023,240633,DB01026,Ketoconazole
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.6,240634,DB01026,Ketoconazole
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,1.7,240635,DB01026,Ketoconazole
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,2.7,240636,DB01026,Ketoconazole
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,8.0,240637,DB01026,Ketoconazole
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,7.0,240638,DB01026,Ketoconazole
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,44.3,240639,DB01026,Ketoconazole
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],41,240640,DB01026,Ketoconazole
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],337,240641,DB01026,Ketoconazole
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,13.5,240642,DB01026,Ketoconazole
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,3.4,240643,DB01026,Ketoconazole
,25100135,clearance,This correlated with an increased clearance with rifampin (39.6-59.8 L/h) and a decreased clearance with ketoconazole (20.3-12.0 L/h).,"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25100135/),[l] / [h],39.6-59.8,241286,DB01026,Ketoconazole
,25100135,clearance,This correlated with an increased clearance with rifampin (39.6-59.8 L/h) and a decreased clearance with ketoconazole (20.3-12.0 L/h).,"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25100135/),[l] / [h],20.3-12.0,241287,DB01026,Ketoconazole
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],3.0 to 6.0,244163,DB01026,Ketoconazole
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.4 to 13.4,244164,DB01026,Ketoconazole
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],38.2 to 88.3,244165,DB01026,Ketoconazole
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],88.3 to 217.2,244166,DB01026,Ketoconazole
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],5.2 to 1.5,244167,DB01026,Ketoconazole
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.8 to 1.9,244168,DB01026,Ketoconazole
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],62.4 to 14.4,244169,DB01026,Ketoconazole
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],87.8 to 19.6,244170,DB01026,Ketoconazole
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],8.7,247154,DB01026,Ketoconazole
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],6.0,247155,DB01026,Ketoconazole
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247156,DB01026,Ketoconazole
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],19,247157,DB01026,Ketoconazole
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247158,DB01026,Ketoconazole
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],30,247159,DB01026,Ketoconazole
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,12.21,248271,DB01026,Ketoconazole
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.39-17.03,248272,DB01026,Ketoconazole
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,10.68,248273,DB01026,Ketoconazole
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,6.96,248274,DB01026,Ketoconazole
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.52,248275,DB01026,Ketoconazole
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB01026,Ketoconazole
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB01026,Ketoconazole
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB01026,Ketoconazole
,31089768,AUC,The AUC of PZQ was increased by 75% with KTZ co-administration (3516 vs 6172 ng h/ml) (p < 0.01).,The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],3516,249328,DB01026,Ketoconazole
,31089768,AUC,The AUC of PZQ was increased by 75% with KTZ co-administration (3516 vs 6172 ng h/ml) (p < 0.01).,The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],6172,249329,DB01026,Ketoconazole
,31089768,AUC,"Meanwhile, the mean AUC of trans-4-OH-PZQ increased by 67% (61,749 ng h/ml vs 103,105 ng h/ml) (p < 0.01).",The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],"61,749",249330,DB01026,Ketoconazole
,31089768,AUC,"Meanwhile, the mean AUC of trans-4-OH-PZQ increased by 67% (61,749 ng h/ml vs 103,105 ng h/ml) (p < 0.01).",The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],"103,105",249331,DB01026,Ketoconazole
,22851617,Elimination half-lives,"Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, respectively.","Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851617/),h,6.57,249659,DB01026,Ketoconazole
,22851617,Elimination half-lives,"Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, respectively.","Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851617/),h,0.39,249660,DB01026,Ketoconazole
,22851617,Elimination half-lives,"Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, respectively.","Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851617/),h,1.57,249661,DB01026,Ketoconazole
,18803444,Cmax,"The highest levels of KET in aqueous humor (Cmax, 2.67 microg/mL) were obtained after a 20-min application of KET-CD, 6.1 times greater than that corresponding to the KET-SP at 30 min.",Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803444/),[μg] / [ml],2.67,249978,DB01026,Ketoconazole
,18803444,Peak KET concentration,"Peak KET concentration in the cornea (118.24 microg/g) was achieved within 5 min after the instillation of KET-CD, 18.4 times higher than that of KET-SP at the same time point, whereas the highest KET level in cornea was only 8.57 microg/g after a 10-min application of KET-SP.",Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803444/),[μg] / [g],118.24,249979,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],179,251609,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],167,251610,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],171,251611,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],147,251612,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],189,251613,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],194,251614,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],181,251615,DB01026,Ketoconazole
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],201,251616,DB01026,Ketoconazole
,11295581,bioavailability,"The faster absorption and improved bioavailability of cyclosporine (around 40%) with Neoral compared with Sandimmune was not seen in patients receiving ketoconazole, where in fact cyclosporine bioavailability was already maximal.",Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),%,40,251617,DB01026,Ketoconazole
<,7967726,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967726/),h,1,251638,DB01026,Ketoconazole
,7967726,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967726/),h,13,251639,DB01026,Ketoconazole
,16390352,plasma C(max),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],45 to 150,252117,DB01026,Ketoconazole
,16390352,clearance (Cl/F),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],138 to 22,252118,DB01026,Ketoconazole
,16390352,plasma C(max),"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],1042 to 205,252119,DB01026,Ketoconazole
,16390352,clearance,"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],65 to 483,252120,DB01026,Ketoconazole
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB01026,Ketoconazole
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB01026,Ketoconazole
,6260830,recovery,The average recovery of ketoconazole over a concentration range of 0.1-20.0 microgram/ml was 88.2 +/- 4.07% S.D.,"Determination of the antifungal agent, ketoconazole, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6260830/),%,88.2,253194,DB01026,Ketoconazole
less,6260830,maximum sensitivity,The maximum sensitivity of the assay is less than 0.1 microgram/ml.,"Determination of the antifungal agent, ketoconazole, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6260830/),[μg] / [ml],0.1,253195,DB01026,Ketoconazole
,11180198,AUC,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[min·μg] / [ml],41.5,253908,DB01026,Ketoconazole
,11180198,AUC,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[min·μg] / [ml],52.5,253909,DB01026,Ketoconazole
,11180198,Cl,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [kg·min],72.2,253910,DB01026,Ketoconazole
,11180198,Cl,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [kg·min],57.1,253911,DB01026,Ketoconazole
,11180198,Cl(int),This was supported by in vitro intrinsic clearance (Cl(int)) of parathion to form paraoxon in hepatic microsomal fraction; the Cl(int) in rats pretreated with dexamethasone was significantly faster (0.0900 compared with 0.0290 mL/min/mg protein) than that in control rats.,Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [mg·min],0.0900,253912,DB01026,Ketoconazole
,11180198,Cl(int),This was supported by in vitro intrinsic clearance (Cl(int)) of parathion to form paraoxon in hepatic microsomal fraction; the Cl(int) in rats pretreated with dexamethasone was significantly faster (0.0900 compared with 0.0290 mL/min/mg protein) than that in control rats.,Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [mg·min],0.0290,253913,DB01026,Ketoconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],94,253963,DB01026,Ketoconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],66.7,253964,DB01026,Ketoconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],47.9,253965,DB01026,Ketoconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],21.7,253966,DB01026,Ketoconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],14.9,253967,DB01026,Ketoconazole
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,97.87,254797,DB01026,Ketoconazole
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,96.74,254798,DB01026,Ketoconazole
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,78.9,254799,DB01026,Ketoconazole
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,86.97,254800,DB01026,Ketoconazole
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,96.46,254801,DB01026,Ketoconazole
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,53.11,254802,DB01026,Ketoconazole
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,7.76,254803,DB01026,Ketoconazole
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,8.33,254804,DB01026,Ketoconazole
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,4.45,254805,DB01026,Ketoconazole
,32534260,flow rate,"Plasma protein precipitation was performed on 5 µL samples, and separation of the analytes was accomplished on an Accucore aQ column using gradient elution at a flow rate of 0.4 mL/min.","Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534260/),[ml] / [min],0.4,255061,DB01026,Ketoconazole
,22352317,hepatic clearance,"The in vivo findings were supported by the result from the test phase where hepatic clearance (4.3 mL min⁻¹ kg⁻¹) was decreased by 29% (metabolism inhibition), 43% (transport inhibition) and 57% (metabolism + transport inhibition).",The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352317/),kg⁻¹·min⁻¹·ml,4.3,255723,DB01026,Ketoconazole
,23523258,Ki,The results indicated that Sch B significantly dose-dependently inhibited rat hepatic microsomal CYP3A activity with Ki value of 16.64 mg/kg and showed the characteristic of a noncompetitive inhibitor.,In vivo effect of Schisandrin B on cytochrome P450 enzyme activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523258/),[mg] / [kg],16.64,258262,DB01026,Ketoconazole
,15116057,clearance,"The mean (+/-SD) clearance values were 35.0 +/- 11.8 L/h (95% confidence interval, 24.1-45.9 L/h) for docetaxel alone and 18.2 L/h (95% confidence interval, 9.22-27.1 L/h) in the presence of ketoconazole, respectively.",Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116057/),[l] / [h],35.0,258728,DB01026,Ketoconazole
,15116057,clearance,"The mean (+/-SD) clearance values were 35.0 +/- 11.8 L/h (95% confidence interval, 24.1-45.9 L/h) for docetaxel alone and 18.2 L/h (95% confidence interval, 9.22-27.1 L/h) in the presence of ketoconazole, respectively.",Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116057/),[l] / [h],18.2,258729,DB01026,Ketoconazole
,15370957,apparent K(m),"2. Midazolam was mainly metabolized by CYP3A in DEX-treated female rat liver microsomes from an immuno-inhibition study, and the apparent K(m) was 1.8 microM, similar to that in human microsomes.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,1.8,262842,DB01026,Ketoconazole
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,0.088,262843,DB01026,Ketoconazole
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,91.2,262844,DB01026,Ketoconazole
,22872575,area under the concentration curve (AUC),"The target sirolimus area under the concentration curve (AUC) of 3,810 ng-h/mL was achieved at sirolimus doses of 90, 16, and 25 mg in the sirolimus alone, sirolimus plus ketoconazole, and sirolimus plus grapefruit juice studies, respectively.",Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22872575/),[ng-h] / [ml],"3,810",262847,DB01026,Ketoconazole
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],10- 12,263027,DB01026,Ketoconazole
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],4.3-4.7,263028,DB01026,Ketoconazole
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,9.7,263029,DB01026,Ketoconazole
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,15,263030,DB01026,Ketoconazole
,19820718,hepatic,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,57.18,263616,DB01026,Ketoconazole
,19820718,hepatic,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,59.29,263617,DB01026,Ketoconazole
,19820718,intestinal extraction ratio,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,54.94,263618,DB01026,Ketoconazole
,19820718,intestinal extraction ratio,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,54.20,263619,DB01026,Ketoconazole
,23584886,AUC ratio,"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,8,264678,DB01026,Ketoconazole
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,0.97,264679,DB01026,Ketoconazole
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,17,264680,DB01026,Ketoconazole
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,0.90,264681,DB01026,Ketoconazole
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],15,265254,DB01026,Ketoconazole
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],59,265255,DB01026,Ketoconazole
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],90,265256,DB01026,Ketoconazole
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],1324,265257,DB01026,Ketoconazole
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,30,265258,DB01026,Ketoconazole
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,56,265259,DB01026,Ketoconazole
,22538054,Bioavailability,Bioavailability of budesonide without inhibition was 27(12-42)%.,Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),%,27,267650,DB01026,Ketoconazole
,22538054,bioavailability,"At the two highest doses (128 mg and above) bioavailability approached 100%, showing that budesonide was completely absorbed from jejunum.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),%,100,267651,DB01026,Ketoconazole
,22538054,extraction ratios,"Applying sigmoid E(max)-models of the mean inhibitions in mucosa and liver indicated that, in this study performed under fed conditions, their uninhibited extraction ratios of budesonide were approximately 0.32 and 0.60, respectively.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),,0.32,267652,DB01026,Ketoconazole
,22538054,extraction ratios,"Applying sigmoid E(max)-models of the mean inhibitions in mucosa and liver indicated that, in this study performed under fed conditions, their uninhibited extraction ratios of budesonide were approximately 0.32 and 0.60, respectively.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),,0.60,267653,DB01026,Ketoconazole
,3428348,elimination half-life,"The mean elimination half-life of the drug was 3.3 h, and although the ketoconazole was given only once daily, a satisfactory clinical response was obtained in all seven individuals.",The pharmacokinetics of ketoconazole after chronic administration in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428348/),h,3.3,268382,DB01026,Ketoconazole
∼5,30862625,high-affinity,"MVC showed significant active uptake and biliary excretion in sandwich-cultured human hepatocytes, and biphasic organic anion transporting polypeptide (OATP)1B1-mediated uptake kinetics in transfected cells (high-affinity K m ∼5 µM).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),,µ,270037,DB01026,Ketoconazole
∼5,30862625,K m,"MVC showed significant active uptake and biliary excretion in sandwich-cultured human hepatocytes, and biphasic organic anion transporting polypeptide (OATP)1B1-mediated uptake kinetics in transfected cells (high-affinity K m ∼5 µM).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),,µ,270038,DB01026,Ketoconazole
,30862625,"inactivation constant, K I","TVR inhibited OATP1B1-mediated MVC transport in vitro, and also exhibited CYP3A time-dependent inhibition in human hepatocytes (inactivation constant, K I = 2.24 µM, and maximum inactivation rate constant, k inact = 0.0112 minute-1).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),μM,2.24,270039,DB01026,Ketoconazole
,30862625,"maximum inactivation rate constant, k inact","TVR inhibited OATP1B1-mediated MVC transport in vitro, and also exhibited CYP3A time-dependent inhibition in human hepatocytes (inactivation constant, K I = 2.24 µM, and maximum inactivation rate constant, k inact = 0.0112 minute-1).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),1/[min],0.0112,270040,DB01026,Ketoconazole
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB01026,Ketoconazole
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB01026,Ketoconazole
,21148045,terminal half-life,Ketoconazole coadministration decreased the mean apparent clearance of bosutinib approximately 9-fold and increased the mean (SD) terminal half-life from 46.2 (16.4) hours to 69.0 (29.1) hours.,Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21148045/),h,46.2,272526,DB01026,Ketoconazole
,21148045,terminal half-life,Ketoconazole coadministration decreased the mean apparent clearance of bosutinib approximately 9-fold and increased the mean (SD) terminal half-life from 46.2 (16.4) hours to 69.0 (29.1) hours.,Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21148045/),h,69.0,272527,DB01026,Ketoconazole
,8742233,steady-state plasma concentrations,"To make a valid comparison, differences in pharmacokinetic properties between the azoles were accounted for by using an infusion approach to maintain steady-state plasma concentrations over a range of 1-48 mg/liter.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),[mg] / [l],1-48,272847,DB01026,Ketoconazole
,8742233,Ki,"Analysis of these data provided Ki values of 3 and 10 microM, for ketoconazole and fluconazole, respectively, based on plasma concentration of azole.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,3,272848,DB01026,Ketoconazole
,8742233,Ki,"Analysis of these data provided Ki values of 3 and 10 microM, for ketoconazole and fluconazole, respectively, based on plasma concentration of azole.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,10,272849,DB01026,Ketoconazole
,8742233,Ki,"Ki values based on unbound drug concentration are 0.07 and 8.7 microM for ketoconazole and fluconazole, respectively.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,0.07,272850,DB01026,Ketoconazole
,8742233,Ki,"Ki values based on unbound drug concentration are 0.07 and 8.7 microM for ketoconazole and fluconazole, respectively.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,8.7,272851,DB01026,Ketoconazole
